# Dasa

# Consolidated interim financial information as at March 31, 2021

(A free translation of the original report in Portuguese, as filled with the Brazilian Securities Commission (CVM), prepared in accordance with the Technical Pronouncement CPC 21 (R1) - Interim Financial Reporting and the international standard IAS 34 - Interim Financial Reporting, as issued by the International Accounting Standards Board - IASB)

# Contents

Report on review of quarterly information	3
Management report	5
Statements of financial position	11
Statements of profit or loss	12
Statements of comprehensive income	13
Statements of changes in equity	14
Statements of cash flows	15
Statement of added value	16
Notes to individual and consolidated interim financial information	17



KPMG Auditores Independentes
Rua Arquiteto Olavo Redig de Campos, 105, 6º andar - Torre A
04711-904 - São Paulo/SP - Brasil
Caixa Postal 79518 - CEP 04707-970 - São Paulo/SP - Brasil
Telefone +55 (11) 3940-1500
kpmg.com.br

# Report on Review of Quarterly Information

(A free translation of the original report in Portuguese, as filled with the Brazilian Securities Commission (CVM), prepared in accordance with the Technical Pronouncement CPC 21 (R1) - Interim Financial Reporting and the international standard IAS 34 - Interim Financial Reporting, as issued by the International Accounting Standards Board - IASB)

To the Shareholders and Management of **Diagnósticos da América S.A.**Barueri - SP

#### Introduction

We have reviewed the individual and consolidated interim financial information of Diagnósticos da América S.A. ("the Company"), included in the Quarterly Information Form (ITR) for the quarter ended March 31, 2021, comprising the statement of financial position as at March 31, 2021 and the respective statements of profit or loss and comprehensive income, changes in shareholder's equity and cash flows for the three-month period then ended, including the explanatory notes.

Management is responsible for the preparation of the individual interim financial information in accordance with the Technical Pronouncement CPC 21 (R1) - Interim Financial Reporting and of the consolidated interim financial information in accordance with the Technical Pronouncement CPC 21 (R1) - Interim Financial Reporting and the international standard IAS 34 - Interim Financial Reporting, as issued by the International Accounting Standards Board - IASB, such as for the presentation of these information in accordance with the standards issued by the Brazilian Securities Commission - CVM, applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on these interim financial information based on our review.

#### **Review scope**

We conducted our review in accordance with the Brazilian and International standards on reviews of interim financial information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the auditing standards and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



#### Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual interim financial information included in the Quarterly Information - ITR referred to above has not been prepared, in all material respects, in accordance with CPC 21 (R1) Technical Pronouncement - Interim Financial Reporting, applicable to the preparation of Quarterly Information - ITR, and presented in accordance with the standards issued by the Brazilian Securities Commission - CVM.

#### Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information included in the Quarterly Information - ITR referred to above has not been prepared, in all material respects, in accordance with CPC 21 (R1) - Interim Financial Reporting and IAS 34 - Interim Financial Reporting, applicable to the preparation of Quarterly Information - ITR, and presented in accordance with the standards issued by the Brazilian Securities Commission - CVM.

#### Other matters - Statements of added value

The quarterly information referred to above includes the individual and consolidated statements of added value (DVA) for the nine-month period ended at March 31, 2021, prepared under responsibility of Company's management, and presented as supplementary information for IAS 34 - Interim Financial Reporting purposes. These statements were submitted to review procedures carried out together with the review of the Company's interim financial information to conclude that they are reconciled with interim financial information and accounting records, as applicable, and its form and content are in accordance with the criteria defined in CPC 09 Technical Pronouncement - Statement of Added Value. Based on our review, nothing has come to our attention that causes us to believe that those statements were not prepared, in all material respects, in accordance with the criteria set forth in this Standards and consistently with respect to the individual and consolidated interim financial information taken as a whole.

São Paulo, May 13, 2021

KPMG Auditores Independentes CRC 2SP014428/O-6 (Original report in Portuguese signed by) Leonardo Augusto Giusti Accountant CRC 1SP203952/O-9

#### Dear Shareholder,

We present below the main figures for the **first** quarter of 2021.

#### **Gross operating revenue**

The DASA Group's consolidated gross revenue in the first quarter of 2021 reached R\$ 2,565.5 million, representing an increase of 60.9% compared to 1Q20. This growth is the result of the robust performance and growth in the business segments, reflecting a recovery in the number of patients at hospitals and the strong upswing in demand for medical exams recorded since 3Q20 and 4Q20, reflecting the large increase in direct users who use Dasa's services.

### **Costs and Gross Profit**

In the first quarter of 2021, the costs of services rendered totaled R\$ 1,659.2 million, equivalent to 69.8% of net operating revenue, accounting for an increase of 56.0% when compared to the costs of the first quarter of the previous year. In the first quarter of 2021, gross profit reached R\$ 717.3 million, an increase of 82.5% compared to the same period of 2020, when we reached gross income of R\$ 393.1 million.

#### Administrative and general expenses

Administrative and general expenses totaled R\$ 675.0 million in the first quarter of 2021, representing 28.4% of net operating revenue. In relation to the first quarter of 2020, there was an increase of 78.2% and, in that quarter, expenses represented 26.0% of net operating revenue.

### **EBITDA**

We reached an EBITDA of R\$ 263.5 million in the first quarter of 2021, which accounts for an increase of 45.7% in relation to the amount of R\$ 180.9 million in the same period of the previous year. In this quarter of 2021, we reached a margin of 11.1%, compared to the 12.4% margin in the first quarter of previous year. EBITDA was impacted by the effects of the COVID-19 pandemic, as mentioned above.

In millions of R\$	1Q21	1Q20	Δ %	Accumulated 2021	Accumulated 2020	Δ %
Net loss for the period	(10.9)	(77.5)	-85.9%	(10.9)	(77.5)	-85.9%
(+) Income tax and social contribution	(60.6)	(46.0)	31.8%	(60.6)	(46.0)	31.8%
(+) Net finance costs	124.0	139.8	-11.3%	124.0	139.8	-11.3%
(+) Depreciation and amortization	211.1	164.5	28.3%	211.1	164.5	28.3%
EBITDA (R\$ MM)	263.5	180.9	45.7%	263.5	180.9	45.7%
EBITDA margin (%)	11.1%	12.4% -	·1.3 p.p.	11.1%	12.4%	-1.3 p.p.

On December 31, 2020, DASA Group consolidated the eleven-month P/L of the acquired company Impar Serviços Hospitalares S.A., based on the acquisition date thereof, as disclosed in Note 2. EBITDA for this eleven-month period represented an amount of R\$ 191.9 million; EBITDA for 2020, considering all twelve months, was R\$ 216.4 million. In order to calculate contractual indices according to the contractual clause and to inform other interested parties, DASA Group will consider the twelve-month EBITDA, in the amount of R\$ 216.4 million.

### Net finance costs

In 1Q21, R\$ 124.0 million was recorded as net finance costs, compared to a negative R\$ 139.8 million in 1Q20 – an 11.3% decrease.

The increase in this line occurred due to the consolidation of Impar's figures in the DASA Group's results as of February 2020, exchange-rate changes, and funding obtained during March 2021, with the purpose of providing greater liquidity at a time of greater economic uncertainty.

#### Deferred income tax and social contribution

The income tax and social contribution was negative by R\$ 60.6 million in the first quarter of 2021, compared to the positive result of R\$ 46.0 million in the first quarter of the previous year.

#### Net income

We recorded a net loss of R\$ 10.9 million for this first quarter of 2021, compared to a loss of R\$ 77.5 million reported in the same period of last year. DASA Group's profit was directly impacted by the COVID-19 pandemic.

#### **Cash and Financial Investments**

We ended the first quarter of 2021 with a cash position and highly liquid interest earning bank deposits of R\$ 1,563.4 million, which will be used to: guarantee the expansion and modernization of the existing units; inaugurate new units and replace imaging equipment; and investments to improve quality, pay financial commitments.

### **Investments**

Net CAPEX investments totaled R\$ 145.5 million in the first quarter of 2021. The investments for the period were mainly directed to: (i) implementation and development of the production and service systems and renovation of the technology park, in the amount of R\$ 18.1 million in the quarter, (ii) renovation and expansion of existing care units and new units, in the amount of R\$ 95.3 million in the quarter and (iii) purchase of medical equipment and other, in the amount of R\$ 32.0 million in the quarter.

#### **Indebtedness**

DASA Group's net debt amounted to R\$ 4,203.3 million in 1Q21, compared to R\$ 2,842.7 million in 1Q20. This increase is explained by the consolidation of Impar's figures in DASA

Group's results and by the use of cash in the period to meet the needs for investments, working capital and acquisitions.

Indebtedness								
		1Q21	1Q20					
	Loans and borrowings	655,343	217,026					
CURRENT LIABILITIES	Debentures	466,458	165,726					
	Derivative financial instruments	2,717	3,032					
	Loans and borrowings	1,014,095	376,383					
NON-CURRENT LIABILITIES	Debentures	3,692,056	3,161,480					
Emblerites	Derivative financial instruments	7,584	8,769					
CURRENT ASSETS	(-) Derivative financial instruments	(18,590)	(7,685)					
NON-CURRENT ASSETS	(-) Derivative financial instruments	(53,009)	(81,305)					
Total	gross debt = A	5,766,654	3,843,426					
Cash and Fin	ancial Investments = B	1,563,356	1,000,748					
Net deb	t (A - B) =	4,203,298	2,842,678					

### Relevant events in the quarter

### **Public Offering**

On March 23, 2021, DASA Group's Board of Directors conducted a public offering for primary and secondary distribution of up to 68,412,943 common shares, all registered, book-entry and without par value, unobstructed and clear of any liens or encumbrances ("Shares"), issued by DASA Group, without prejudice to the Additional Shares (as defined in the Resolutions), with restricted placement efforts, to be conducted in the Federative Republic of Brazil ("Brazil"), under Brazilian Securities and Exchange Commission ("CVM") Instruction 476 of January 16, 2009, as amended ("CVM Instruction 476"), with efforts to place Shares abroad ("Restricted Offer"); such issuance will be carried out within the limit of authorized capital provided for in Article 6, introductory paragraph, of the Articles of Organization.

### Acquisition of Hospital São Domingos

On March 12, 2021, DASA Group announced that on that date it completed – through İmpar Serviços Hospitalares S.A., a wholly-owned subsidiary of DASA Group and a privately-held company – the acquisition of 100% (one hundred percent) of the shares representing the capital of São Domingos Group, including the shareholdings of Hospital São Domingos Ltda., Neuro imagens Ltda., and Clínica Solução Médica Ltda.

# Seventh Issuance Promissory Note

On March 8, 2021, the 7th issuance of PN was settled by DASA Group, as the issuer of 500 (five hundred) commercial promissory notes of the DASA Group's seventh issuance totaling R\$ 500 million. The term of promissory notes will be one hundred and eighty (180) days as of issuance date.

### Migration in the Novo Mercado

On February 23, 2021, the Extraordinary General Meeting of shareholders representing 98.5753% (ninety-eight point five-seven-five-three percent) of the voting capital of DASA Group, decided – by unanimous vote of the attending shareholders, with no abstentions or votes against, and without reservations, with 473,873,274 (four hundred seventy-three million, eight hundred seventy-three thousand, two hundred seventy-four) votes in favor, corresponding to 98.5753% (ninety-eight point five-seven-five-three percent) of the voting capital of DASA Group – to approve the submission of DASA Group's application for migration to the Novo Mercado of the B3 stock exchange.

# **Election of Director**

On February 5, 2021, DASA Group's Board of Directors elected Ms. Ana Elisa Alvares Correa de Siqueira to serve as Chief Officer of Integrated Care Operations; Ms. Andréa Rezende Dolabela as Chief Officer of Products and Marketing; Mr. Sérgio Ricardo Rodrigues de Almeida Santos as Chief Strategy Officer; and Mr. Adam Oliveira Alves as Chief Commercial Officer.

#### Director resignation

On January 27, 2021, the DASA Group's Board of Directors was informed of the resignation request submitted by Mr. Diego Alvarez Araujo Correia, Information Technology Chief Officer of DASA Group, and stated that his resignation was effective as of the end of December 18, 2020.

#### Acquisition of Gesto Saúde

On January 15, 2021, DASA Group informed its shareholders and the market in general that it had completed DASA's acquisition of all of the shares held by the Sellers representing 100% (one hundred percent) of the capital of Gesto Saúde (Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda.).

### Acquisition of Innova.

On January 6, 2021, DASA Group announced that on that date it had competed – through ÍMPAR SERVIÇOS HOSPITALARES S.A., a wholly-owned subsidiary of DASA Group and a privately-held company – the acquisition of 100% (one hundred percent) of the shares representing the total capital of Innova Hospital Associados Ltda., a limited liability company; as a result, said Company is now wholly owned by DASA.

### Election of Director

On January 4, 2021, DASA Group's Board of Directors elected Mr. Fabio Rose to serve as Chief Officer of People and Culture at DASA Group.

### Relevant subsequent events

### Merger - Insitus

On May 3, 2021, DASA Group communicated to its shareholders and the market in general that it had completed the take-over of the entire ownership equity of DASA's subsidiary, Insitus Serviços Médicos e Laboratoriais Ltda., a limited liability company, with registered offices in the city of Sao Paulo.

### Restricted offer

On April 6, 2021, DASA Group's Board of Directors approved the increase in DASA Group's capital in the amount of R\$ 3,306 million, through the issuance of 57,010,786 (fifty-seven million, ten thousand, seven hundred eighty-six) new common shares, all registered, book-entry, and without par value.

On May 10, 2021, DASA Group's Board of Directors informed its shareholders and the market in general that the number of Shares initially offered was increased by a supplementary lot equivalent to 10.88% of the total Shares initially offered, i.e., 6,200,817 common shares issued by DASA Group, under the same conditions and for the same price as the Shares initially offered, due to the partial exercise of the Supplementary Shares Option, earmarked exclusively for activities to stabilize the price of common shares issued by DASA Group.

The result of the Offer consisted of the total distribution of 63,211,603 Shares offered at a Price Per Share of R\$ 58.00, as approved at a meeting of DASA Group's Board of Directors held on April 7, 2021, totaling R\$ 3,666 million.

### Acquisition of Grupo Carmo.

On April 1, 2021, DASA Group announced that on that date it completed – through ÍMPAR SERVIÇOS HOSPITALARES S.A., a wholly-owned subsidiary of DASA Group and a privately-held company – the acquisition of 70% (seventy percent) of the shares representing the capital of Nossa Senhora do Carmo Participações S.A.

### Projections and non-accounting data

The assertions contained in this document related to business prospects, projections of operating and financial results, as well as those related to the DASA Group's growth prospects, are merely projections and, as such, are based exclusively on the management's expectations about the future of the businesses. This performance report includes non-accounting data and accounting data such as, operational, financial and projections based on the expectations of the DASA Group's management. Non-accounting data was not subject to audit by the independent auditors of DASA Group.

#### **Additional information**

The financial information is presented in millions of reais, unless otherwise indicated. The individual and consolidated interim financial information of Dasa Group was prepared in accordance with CPC 21 (R1) - Interim Statement and consolidated in accordance with CPC 21 (R1) - Interim Statement and IAS 34 – Interim Financial Reporting, issued by the International Accounting Standard Board (IASB) and presented consistently with standards issued by the Securities Commission applicable to the preparation of Quarterly Information – ITR.

### **Executive Board's Statement**

### **Arbitration Clause**

DASA Group is subject to arbitration in the court of arbitration of the market, pursuant to an arbitration clause contained in Article 35 of its bylaws.

### Statement of the Executive Board

In compliance with the provisions contained in CVM Instruction 480 of December 7, 2009, the Executive Board hereby states that it discussed, reviewed and agreed with the individual and consolidated interim financial information, as well as the audit report of the independent auditors' review issued as to the respective individual and consolidated interim financial information for the three-month period ended March 31, 2021.

# **Statements of financial position**

As at March 31, 2021 and December 31, 2020

(in thousands of Reais)



		Parent	Company	Cons	solidated			Parent	Company	Cons	olidated
	Note	March, 2021	December, 2020	March, 2021	December, 2020		Note	March, 2021	December, 2020	March, 2021	December, 2020
CURRENT ASSETS						CURRENT LIABILITIES					
Cash and cash equivalents	5	229,640	143,045	751,039	753,607	Trade payables	14	486,109	535,942	849,509	893,175
Marketable securities	6	796,627	740,916	812,317	760,816	Loans and borrowings	15	547,218	46,211	655,343	200,194
Trade receivables	7	825,339	903,728	1,739,556	1,743,233	Debentures	17	460,842	145,133	466,458	145,720
Inventories	8	200,191	169,841	394,169	357,800	Tax liabilities		64,280	96,573	133,456	185,333
Taxes recoverable	9	131,500	116,742	302,810	260,035	Income tax and social contribution		4,365	4,365	28,130	19,210
Prepaid expenses		25,547	10,159	47,752	12,178	Social and labor obligations		217,710	258,610	455,892	495,668
Derivative financial instruments	30	-	-	18,590	26,201	Taxes in installments	18	2,494	2,627	27,996	23,150
Call option obtained from non-controlling shareholders	19	4,248	6,147	4,248	6,147	Accounts payable from acquisition of subsidiaries	19	163,841	116,638	173,020	121,408
Other receivables	10	111,504	89,588	391,438	290,854	Dividends and interest on own capital	22	123,816	116,627	211,365	224,146
						Derivative financial instruments	30	-	-	2,717	1,856
						Provision for loss in subsidiaries	11	36,330	46,798	-	-
						Leases payables	16	379,333	294,843	503,260	427,238
						Share-based payments	21	155,631	32,581	155,631	32,581
						Put option granted to non-controlling shareholders	19	34,638	33,768	34,638	33,768
						Other accounts payable and provisions		107,138	126,244	249,411	209,665
TOTAL CURRENT ASSETS		2,324,596	2,180,166	4,461,919	4,210,871	TOTAL CURRENT LIABILITIES		2,783,745	1,856,960	3,946,826	3,013,112
NON-CURRENT ASSETS						NON CURRENT LIABILITIES					
Trade receivables	7	6,686	881	8,458	2,653	Loans and borrowings	15	633,971	629,180	1,014,095	1,001,621
Taxes recoverable	28	380,886	319,799	522,051	448,790	Debentures	17	3,092,779	3,392,076	3,692,056	3,991,288
Prepaid expenses		2,109	4	2,775	607	Taxes in installments	18	4,160	4,596	56,774	61,926
Judicial deposits	20	81,211	81,081	101,757	100,303	Deferred tax liabilities	28	_	· · · · · · · · · · · · · · ·	26,185	8,502
Recoverable taxes	9	27,070		33,678	20,275	Provision for labor, civil and tax security claims	20	149,566	123,941	213,699	201,418
Financial investments - escrow	19	38,547	38,386	38,666	38,505	Accounts payable from acquisition of subsidiaries	19	343,657	408,218	378,299	415,395
Derivative financial instruments	30	-	-	53,009	39,203	Trade payables	14	13,712	13,712	15,357	15,461
Related parties	31	16,170	13,586	_	_	Derivative financial instruments	30	_	_	7,584	5,603
Call option obtained from non-controlling shareholders	19	1,175	1,322	1,175	1,322	Leases payables	16	509,940	562,640	1,088,711	1,058,275
Other receivables	10	6,668	8,992	7,181	13,414	Share-based payments	21	33,710	7,181	33,710	7,181
						Put option granted to non-controlling shareholders	19	6,069	5,691	6,069	5,691
						Other accounts payable and provisions		7,762	9,106	15,507	21,495
TOTAL LONG TERM ASSETS		560,522	464,051	768,750	665,072	TOTAL NON-CURRENT LIABILITIES		4,795,326	5,156,341	6,548,046	6,793,856
						TOTAL LIABILITIES		7,579,071	7,013,301	10,494,872	9,806,968
Investments	11	3,699,071	3,408,761	5,607	4,332	Share capital	22	12,326,706	12,326,706	12,326,706	12,326,706
Property, plant and equipment	12	1,060,622	1,083,675	2,650,346	2,608,954	Capital reserves	22	431,487	431,487	431,487	431,487
Right of use assets	16	826,125	796,876	1,476,421	1,384,934	Equity valuation adjustment	22	(9,563,560)	(9,552,209)	(9,563,560)	(9,552,209)
Intangible assets	13	2,635,454	2,616,003	4,660,883	4,469,333	Retained earnings	22	332,686	330,247	332,686	330,247
		8,221,272	7,905,315	8,793,257	8,467,553	TOTAL SHAREHOLDERS' EQUITY		3,527,319	3,536,231	3,527,319	3,536,231
TOTAL NON-CURRENT ASSETS		8,781,794	8,369,366	9,562,007	9,132,625	Non-controlling interest		-	-	1,735	297
TOTAL ASSETS		11,106,390	10,549,532	14,023,926	13,343,496	TOTAL LIABILITIES AND SHAREHOLDER'S EQ	DUITY	11,106,390	10,549,532	14.023,926	13,343,496

# Statements of profit or loss

For the periods ended March 31, 2021 and 2020

(In thousands of Brazilian Reais, except for loss per share)



	j	Parent Company		Consolidated		
	Note	March, 2021	March, 2020	March, 2021	March, 2020	
Net revenue from services	23	1,180,279	795,521	2,376,514	1,456,868	
Cost of services rendered	24	(771,512)	(555,541)	(1,659,207)	(1,063,752)	
Gross profit		408,767	239,980	717,307	393,116	
Administrative and general expenses	25	(458,362)	(246,681)	(674,994)	(378,681)	
Other operating income	26	1,234	751	11,341	3,514	
Other operating expenses	26	(334)	(1,320)	(1,227)	(1,639)	
Operating (loss) profit		(48,695)	(7,270)	52,427	16,310	
Financial income	27	48,298	7,774	56,091	79,990	
Financial expenses	27	(120,801)	(135,611)	(180,051)	(219,796)	
Net finance costs		(72,503)	(127,837)	(123,960)	(139,806)	
Equity accounting income	11	40,041	2,606	-	-	
Equity results from investees		40,041	2,606	-	-	
Loss before income tax and social contribution		(81,157)	(132,501)	(71,533)	(123,496)	
Deferred income tax and social contribution	28	68,785	54,366	79,919	54,624	
Income tax and social contribution	28	-	-	(19,294)	(8,616)	
(Loss) Profit		(12,372)	(78,135)	8,386	(68,872)	
Result attributable to:						
Controlling shareholders Non-controlling interests		(12,372)	(78,135)	(12,372) 1,464	( <b>78,135</b> ) 647	
Non-controlling interests		-	-	1,404	047	
Loss for the period		(12,372)	(78,135)	(10,908)	(77,488)	
Earnings per share						
Basic loss per share (in R\$)	22	-	-	(0.02269)	(0.16120)	
Diluted loss per share (in R\$)	22	-	-	(0.02138)	(0.15479)	
Number of shares - basic	22	-	-	480,722	480,705	
Number of shares - diluted	22	-	-	510,167	500,607	

# **Statements of comprehensive income**

For the periods ended March 31, 2021 and 2020

(in thousands of Reais)



	Parent Co	ompany	Consolidated		
	March, 2021	March, 2020	March, 2021	March, 2020	
Loss for the period	(12,372)	(78,135)	(10,908)	(77,488)	
Cumulative translation adjustment	13,883	54,489	13,883	54,489	
Effect of applying CPC42/IAS29 - Hyperinflation	(14,811)	13,733	(14,811)	13,733	
Total comprehensive loss for the period	(13,300)	(9,913)	(11,836)	(9,266)	
Comprehensive loss attributed owners of the Company	-		(13,300)	(9,913)	
Comprehensive income attributed non-controlling interests	-		1,464	647	

# Statements of changes in equity

For the periods ended March 31, 2021 and 2020 (in thousands of Reais)



		Parent Company									
				Earnings	reserves						
	Note	Share Capital	Capital reserve	Legal reserve	Retained Earnings	Profit retention	Equity valuation adjustment	Total parent company	Non- controlling interest	Total consolidated	
Balance at December 31, 2019		2,326,423	430,347	62,204	556,042		(102,787)	3,272,229	(8,846)	3,263,383	
Capital increase	24	10,000,283	-	-	-	-	(9,243,944)	756,339	-	756,339	
Loss for the period		-	-	-	-	(78,135)	-	(78,135)	(743)	(78,878)	
Cumulative translation adjustment	24	-	-	-	-	-	54,489	54,489	-	54,489	
Effect of applying CPC42 / IAS29 - Hyperinflation	24	-	-	-	-	-	13,732	13,732	-	13,732	
Balance at March 31, 2020		12,326,706	430,347	62,204	556,042	(78,135)	(9,278,510)	4,018,654	(9,589)	4,009,065	
Balance at December 31, 2020		12,326,706	431,487	62,204	268,043	<u> </u>	(9,552,209)	3,536,231	297	3,536,528	
Shareholder transaction							(10,423)	(10,423)	_	(10,423)	
Loss for the period		_	_	_	_	(12,372)	(10,123)	(12,372)	1,464	(10,908)	
Cumulative translation adjustment	22	-	_	-	_		13,883	13,883	(26)	13,857	
Effect of applying CPC42 / IAS29 - Hyperinflation	22	-	-	-	-	14,811	(14,811)	-	- ′	-	
Absorption of accumulated losses		-	-	=	2,439	(2,439)	-	-	-	-	
Balance at March 31, 2021		12,326,706	431,487	62,204	270,482		(9,563,560)	3,527,319	1,735	3,529,054	

# Statements of cash flows

For the periods ended March 31, 2021 and 2020 (in thousands of Reais)



	Parent Co	ompany	ompany Consolidate	
	March, 2021	March, 2020	March, 2021	March, 2020
Cash flow from operating activities				
Loss for the period	(12,372)	(78,135)	(10,908)	(77,488)
Adjustments for:	120.100	110042	211.051	165.400
Depreciation and amortization	130,190	118,943	211,051	165,408
Provision for labor, civil and tax security claims	15,641	14,227	4,434	13,550
Income tax and social contribution - current and deferred Interest and exchange-rate change from loans and accounts payable from	(68,785)	(54,366)	(60,625)	(52,699)
acquisition of subsidiaries	51,797	103,451	79,040	182,881
Derivative financial instruments results	=	-	(14,190)	(48,064)
Gain on the sale of fixed and intangible assets	130	165	1,454	8,112
Share-based payments	151,136		151,136	-
Share of profit of equity-accounted investees	(40,041)	(2,606)	-	-
Expected credit losses of trade receivables	(8,393)	318	(8,362)	1,070
Expected disallowance - variable consideration	2,907	22,945	4,055	48,704
Interest and exchange-rate change from interest earning bank deposits	(2,703)	(2,124)	(3,516)	(3,046)
Judicial deposits	(130)	-	-	-
Provision for loss of inventories	(255)	2,421	(220)	3,071
Interest on leasing - IFRS 16	20,866	21,753	44,448	28,699
Decrease (Increase) in trade receivables	78,070	(39,761)	6,238	(11,872)
Increase in inventories	(30,095)	(13,921)	(34,957)	(45,621)
Increase in other current assets	(47,710)	(32,898)	(74,490)	(43,428)
Increase in other non-current assets	(20,911)	(19,538)	(2,586)	(4,662)
Decrease in trade payables	(72,879)	(66,916)	(76,155)	(90,474)
Decrease in other trade payable and provisions	(101,245)	(57,452)	(62,531)	(52,961)
Shared based payments	(1,557)	(17,580)	(1,557)	(17,580)
Income tax and social contribution paid  Net cash generated from (used in) operating activities	43,661	(101,074)	(4,965) 146,794	(6,816)
Net cash generated from (used in) operating activities	45,001	(101,074)	140,774	(3,210)
Cash flow from investing activities				
Acquisition of property, plant and equipment	(19,911)	(25,714)	(74,872)	(93,756)
Acquisition of intangible assets	(37,490)	(29,268)	(41,798)	(32,476)
Advance for future capital increase	(136,000)	7,456	-	-
Cash and cash equivalents of subsidiaries acquired - common control	(105.555)	-	- (161.025)	566,705
Acquisition of subsidiaries, net of cash Interest earning bank deposits	(105,755) (875,450)	(150,816)	(161,937) (873,042)	(267,956)
Redemption of interest earning bank deposits	821,616	201,042	824,601	271,093
Advances for acquisition of subsidiaries	-	201,012	(100,427)	-
Ne cash (used in) generated by investing activities	(352,990)	2,700	(427,475)	443,610
Cash flow from financing activities				
Loans and debentures	500,000	_	499,994	140,000
Payment of loans and debentures	(1,696)	(2,049)	(57,177)	(166,680)
Interest paid on loans and debentures	(8,583)	(26,028)	(13,084)	(29,308)
Receipt of derivative financial instruments	-	-	10,837	
Dividends and interest on equity paid	-	(151,023)	(19,970)	(189,620)
Capital increase	(20.01.0)	283	(41.046)	283
Acquisition of subsidiaries - payments	(39,916)	(54.002)	(41,946)	(72.101)
Leasing payment - IFRS 16  Net cash generated by (used in) financing activities	(53,881) 395,924	(54,882)	(100,541) 278,113	(73,101)
Net cash generated by (used in) mancing activities	393,924	(233,099)	270,113	(310,420)
Net increase (decrease) in cash and cash equivalents	86,595	(332,073)	(2,568)	121,968
Statement of immercial control in such that is a second of the second of				
Statement of increase (decrease) in cash and cash equivalents	142.045	412.060	752 607	567.000
At the beginning of the period	143,045 229,640	413,069 80,996	753,607 751,039	567,809 689,777
At the end of the period	229,040	00,770	131,039	007,///
	86,595	(332,073)	(2,568)	121,968
	00,373	(552,075)	(2,500)	121,700

# Statement of added value

For the periods ended March 31, 2021 and 2020  $\,$ 

(in thousands of Reais)



	Parent C	ompany _	Consoli	idated
	March, 2021	March, 2020	March, 2021	March, 2020
Revenues				
Sale of services redered	1,260,526	873,268	2,565,504	1,594,846
Other operating income	1,363	751	2,910	3,514
Expected credit losses of trade receivables	8,436	(2,838)	11,342	(5,234)
Inputs purchased from third parties				
(Included tax amounts - ICMS, IPI, PIS and COFINS)				
Cost of products and goods sold and services rendered	(822,492)	(370,030)	(1,400,058)	(678,014)
Materials, energy, outsourced services and other	(97,528)	(96,671)	(245,417)	(201,754)
Gross added value	350,305	404,480	934,281	713,358
Depreciation and amortization	(130,190)	(118,976)	(211,051)	(164,548)
Net added value produced	220,115	285,504	723,230	548,810
Added value received as transfer				
Equity results from investees	40,041	2,606	-	-
Finance income	50,165	7,774	57,918	79,990
Total added value payable	310,321	295,884	781,148	628,800
Distribution of added value	310,321	295,884	781,148	628,800
Personnel	243,096	202,308	504,588	362,263
Taxes, rates and contributions	(95,857)	38,443	41,457	121,226
Third-party capital remuneration				
Interest and rentals	175,454	133,267	246,010	222,798
Remuneration of own capital				
(Decrease) in retained earnings in the year	(12,372)	(78,134)	(12,372)	(78,134)
Interest of non-controlling shareholders	-	-	1,465	647

(In thousands of reais, unless otherwise stated)



# 1 Operations

Diagnósticos da América S.A., "Parent Company" or "Company" and together with its subsidiaries "DASA Group", with head office at Avenida Juruá, 434, Alphaville, Zip Code 06455-010, city of Barueri, State of São Paulo, is a publicly-traded corporation registered with the Brazilian Securities Commission (CVM), on November 5, 2004, under trading code DASA3, to trade its shares on the stock exchange.

The Company through its own operations, as well as of its subsidiaries, is engaged in the provision of services:

- I. Outpatient physicians covering on-site and online (telemedicine) medical consultations, outpatient procedures, outpatient procedures with resources to make surgical procedures and complementary examinations and drug administration (therapies) to private patients or member companies, insurance companies, medical-hospital assistance entities or other types of health costing.
- II. Diagnostic support assistants to private patients or member companies, insurance companies, medical-hospital assistance entities, other types of health funding, including clinical analyses and vaccination, directly, or on supplementary basis, through contracted laboratories; as well as other diagnostic support services, solely through specialized health companies, mainly in the areas of: (i) pathologic cytology and anatomy; (ii) diagnostic imaging and graphic methods; and (iii) nuclear medicine.
- III. Provide hospital services; provide medical and outpatient services in its facilities; serve as improvement field for physicians, nurses and other professionals related to these activities; and provide means for scientific research and investigation. The services are rendered through Ímpar, which is controlled by the Company, in the following hospitals: Hospital 9 de Julho, Complexo Hospitalar Niterói, Hospital São Lucas Copacabana, Hospital Brasília, Maternidade Brasília, Hospital Santa Paula, Hospital Águas Claras and Innova Hospitais.
- IV. Provision of services of coordination of care, remote monitoring, population health management, health assistance and paramedic home care and outpatient medical activity restricted to consultations. Consulting to health care companies and providers in the development of health management models, new compensation models, risk control and management of assistance network. The services are rendered through Santa Celina, which is controlled by the Company.
- V. Development and licensing of computer programs, digital products, including applications, data processing and handling, internet service, hosting, development of providers and other related activities, consulting, support, maintenance and other services related to information technology. The services are rendered by the Company through its trademark Nexa.
- VI. Development and licensing of predictive models using information technology and data sciences. The services are rendered through the subsidiaries Genia, Nobeloy and Optiren.
- VII. Provision of services of brokerage, sale of health care plans, data analysis, consulting for reduction of claim and health management to companies. The services are rendered by the Company through its trademarks Dasa Empresas (Allbrokers) and Gesto Saúde.

(In thousands of reais, unless otherwise stated)



VIII. Activities related to (i) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written communication vehicles, aimed at scientific disclosure or activities included in the scope of the Company's operations (ii) granting and management of corporate franchising, including marketing fund and disclosure, training and selection of labor, appointment of suppliers of equipment and research material (iii) realization of analyses in food and substances in order to assess risks to human beings; and (iv) import, for own use, of medical-hospital equipment, sets for diagnoses and the like in general.

For purposes of analysis and decision making by Management, the operations of DASA Group are managed by three segments: (i) outpatient care and coordination of care - especially in relation to economic features, provision of services and production processes, type of customer, suppliers and logistic process, composed of service units and technical centers of operations, (ii) hospitals and oncology - through Impar Serviços Hospitalares S.A., a subsidiary of the Company, composed of hospitals located in the cities of São Paulo, Rio de Janeiro and Brasília, and (iii) International Operations - diagnostic support services, composed of service unit and technical centers of operations located in Argentina and Uruguay. The Board of Directors analyzes the reports at least on quarterly basis.

# Impacts of COVID-19 on the operations of DASA Group

In March 2020, the World Health Organization (WHO) announced that the coronavirus (COVID-19) is a global health emergency and declared it a pandemic. The outbreak triggered significant decisions by governments and private sector entities, which added to the potential impact of the outbreak, increased the level of uncertainty about the economic agents.

Management constantly assesses the impact of the outbreak on operations and on DASA Group equity and financial position, in order to implement appropriate measures to mitigate the impacts of the outbreak on operations and individual and consolidated interim financial information. Until the authorization date for issuance of financial information, the following main measures were taken:

- DASA Group instituted a Crisis Committee and are managing a series of action plans to minimize impacts to its business.
- DASA Group implemented several measures to protect liquidity, including adherence to MP 936, reducing between 25% to 50% of working hours and, in some cases, suspending working hours, in addition to adhering to tax initiatives provided by the Tax Authorities to postpone federal tax payments.
- Management concluded that there are no indicators of impairment of goodwill and assets allocated to Cash Generating Units (CGU). The last test was conducted for the year ended December 31, 2020, as set forth in the respective individual and consolidated annual financial statements, published on March 6, 2021.
- DASA Group reviewed the impact of the crisis on accounts receivable, regarding a possible increase
  in credit risk, but did not identify any relevant impacts arising therefrom for the period under analysis.
  In relation to inventories, DASA Group reviewed the position of inventories as at March 31, 2021 and
  its provision for losses, with no material impact.

(In thousands of reais, unless otherwise stated)



In relation to the realization of deferred tax credits, DASA Group expects no impact, considering its projections for the year ended December 31, 2021, as set forth in the respective individual and consolidated annual financial statements, published on March 6, 2021.

# 2 Acquisitions of subsidiaries

Identifiable assets acquired and liabilities assumed at fair value on the acquisition date, as well as other information necessary to assess the accounting and financial effect of the business combination are shown in the table at the end of this note.

# **Acquisitions in the year 2021**

# Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda. ("Gesto Saúde").

On January 15, 2021, the Company communicated to its shareholders and to the general market that it had concluded the acquisition of all quotas held by the sellers representing 100% of the capital stock of Gesto Saúde.


Gesto Saúde intends to provide brokerage services, marketing health plans, data analysis, claims reduction consulting and health plan management to businesses.

The acquisition was completed for the amount of R\$ 68,120 of which R\$ 64,870 were paid in cash on the date of the contract with R\$ 3,250 to be paid in January 2023.

# Innova Hospitais Associados Ltda. ("Innova")

On January 06, 2021, we announced that on this date the acquisition of 100% of the quotas representing the total share capital of the Company was completed by Impar Serviços Hospitalares S.A., a private corporation wholly owned by the Company.

The acquisition was completed for the amount of R\$ 94,849 of which R\$ 61,286 were paid on the agreement date and R\$ 33,563 will be paid in five annual installments beginning on January 6, 2022.





# Fair value of the assets acquired and assumed liabilities

	<u>Innova</u>	Gesto
Acquisition date Participation acquired	01/06/21 100%	01/15/21 100%
Assets	750	4.245
Cash and cash equivalents Trade receivables	759 3,115	4,345 944
Inventories	1,192	944
Taxes recoverable	-	475
Indemnifiable Asset (a)	-	3,250
Prepaid expenses	-	519
Other receivables (a)	6,383	44
Property, plant and equipment	31,266	1,361
Intangible Assets (a) Right of use assets	-	3,480 2,244
Intangible Assets – Trademark (b)	-	9,958
Intangible Assets – Non-contractual customer relationship (b)	_	22,799
Total identifiable assets acquired	42,715	49,419
Liabilities		
Trade payables	(3,442)	(275)
Loans and borrowings	-	(5)
Income tax and social contribution	-	(1,246)
Social and labor obligations	(5,805)	(244)
Deferred tax liabilities (a)	-	(7,698)
Leases payables Provision for labor, civil and tax security claims (a)	(5,058)	(2,244) (16,809)
Other accounts payable and provisions	(29)	(258)
Total assumed liabilities	(14,334)	(28,779)
Total assumed habilities	(14,554)	(20,777)
Total assets, net	<u>28,381</u>	<u>20,640</u>
Goodwill on acquisition €	66,468	47,480
Total consideration transferred	94,849	<u>68,120</u>
Consideration composition:		
Cash	94,849	68,120
Total assets, net (prior) (f)	34,594	5,698
Total goodwill (prior) (f)	60,255	62,422
Contribution to the Compa-y - Revenues since the beginning of the year	3,927	2,464
Contribution to the Compa-y - Loss since the beginning of the year	(3,159)	(786)


Fair value measurement carried out on provisional bases:

a) The fair value of Gesto's assets acquired and liabilities assumed on the acquisition date is pending conclusion of evaluation by Management.

The fair value of Gesto's intangible assets (trademark and relationship with consumers) was determined on provisional basis and is pending conclusion of independent evaluatio

b) n.

If new information obtained within one year from the acquisition date, regarding facts and circumstances existing on the acquisition date, indicate adjustments in the aforementioned amounts, or any additional provision existing on the acquisition date, the recording of the acquisition will be reviewed.





# Acquisitions in the fiscal year 2020

Identifiable assets acquired and assumed liabies:

	<u>Ímpar</u>	Allbrokers	<u>Nexa</u>	<u>Santa</u> Celina	<u>São</u> Marcos	<b>Exame</b>	<b>Hemat</b>
Acquisition date Participation acquired	01/23/20 100%	02/17/20 100%	05/11/20 100%	06/08/20 60%	0605//20 100%	12/17/20 90%	12/18/20 80%
Call option obtained from non-controlling shareholde–s - updated as at March 31, 2021	-	-	-	-	-	1,000	1,270
Call option granted to non-controlling shareholde-s - updated as at March 31, 2021	-	-	-	-	-	16,552	5,694
Assets							
Cash and cash equivalents  Marketable securities	566,705 1,101	170	2,076	8,083	22,603	4,431	2,831
Trade receivables	529,161	-	-	21,047	52,921	18,607	1,792
Inventories	65,870	-	_	601	4,839		399
Taxes recoverable	26,972	123	37	4,204	10,355	254	5
Prepaid expenses	22,030	-	-	189	491	118	828
Deferred income tax and social contribution	65,962	-	-	858	67	-	-
Derivative financial instruments	41,552	-	-	-	4,185	-	-
Judicial deposits	12,501	-	-	431	2,203	98	-
Other receivables	20,915	76	2,532	2,132	270	142	-
Investments Property, plant and equipment	1.166.240	-	- 510	- 5.047	436	- 200	59
Intangible assets	1,166,249 15,806	-	510 24,002	5,047 4,510	36,065 4,164	6,209 1,025	235 4,602
Right of use	469,304	-	24,002	4,831	37,415	6,118	4,002
Intangible Asse–s - Trademark (a)		1,481	_	31,477	44,282	22,290	3,610
Intangible Asse-s - Non-contractual customer relationship	_	705	_	28,400	14,110	10,472	1,696
Total identifiable assets acquired	3,004,128	2,555	29,157	111,810	234,406	69,764	16,057
Liabilities							
Trade payables	(245,331)	-	-	(5,135)	(16,297)	(3,756)	(1,082)
Loans and borrowings	(440,923)	(3,867)	-	(18,941)	(81,506)	(25,588)	(4,322)
Debentures	(601,571)	-	-	-	-	-	-
Social and labor obligations	(127,294)	(740)	(1,309)	(7,594)	(8,061)	(3,573)	(558)
Income tax and social contribution	(28,667)	-	-	-	-	-	-
Taxes liabilities		-	(24)	(3,611)	(7,982)	(2,440)	(163)
Taxes in installments Deferred tax liabilities	(77,833)	-	-	-	(6,492)	(1,758)	-
Dividends and interest on own capital	(125,157)	-	-	(2,480)	-	(230)	-
Accounts payable from acquisition of subsidiaries	(123,137)	-	-	(2,400)	(2,810)	(9,216)	-
Leases payables	(489,138)	-	-	(5,556)	(40,016)	(6,117)	_
Derivative financial instruments	(12,427)	_	_	(5,550)	(10,010)	(0,117)	-
Provision for labor, civil and tax security claims	(51,206)	-	-	(391)	(2,621)	(61)	-
Other accounts payable	(48,525)	(208)	(3,226)	(244)	(26,414)	(648)	(860)
Total assumed liabilities	(2,248,072)	(4,815)	(4,559)	(44,550)	(192,208)	(53,387)	(6,985)
Total assets, net	756,056	(2,260)	24,598	67,260	42,198	16,377	9,072
Non-controlling intere€(c)	-	-	-	(2,953)	-	1,639	(801)
Goodwill on acquisition (d)	-	9,968	19,102	27,696	106,925	52,401	11,279
Total consideration transferred (f)	-	7,708	43,700	92,003	149,123	70,417	19,550
Consideration composition:	-						
Contingent consideration (Note 20)	-	-	-	-	-	15,300	-
Cash	-	7,708	43,700	70,510	130,000	55,117	19,550
Total assets, net (provisional b€s) (e)	756,056	(2,206)	24,598	41,670	55,530	16,377	9,072
Total goodwill (provisiona€asis) (e)	-	9,968	19,102	31,793	74,470	52,401	11,279
Contribution to -he Company - Revenues since the acquisition date	2,690,793	2 247		56.001	40,050		
Contribution to -he Company - Income since the		3,347	-	56,984		-	-
acquisition date Contribution to –he Company - Revenues since the	(43,378)	(6,997)	-	(17,534)	908	-	-
beginning of the year Contribution to –he Company - Income since the	2,740,256	4,342	-	97,333	175,569	96,336	18,930
beginning of the year.	(39,387)	(7,885)	(6,875)	(25,768)	(600)	32,427	1,875

(In thousands of reais, unless otherwise stated)



- (f) (a) Measured at fair value under the "Relief From Royalty Method" (RRM), which captures savings of royalties associated to holding the trademark, instead of obtaining the license to use it. The intangible had a useful life of 30 to 35 years.
- (b) Non-contractual customer relationship: measured at fair value under the "Multi-Period Excess Earnings Method" (MPEEM). The intangible is originated from the relationship of the acquired company with its customers, which represents a stable and recurring source of income. The intangible has useful life of 4 to 1 years.
- f) c) The noncontrolling interest was estimated by the proportional interest bestowed by equity instruments in the amounts recognized of the identifiable net assets of the acquireompany.
- f) d) The goodwill is attributed mainly to the qualification and technical talent of the labor force and to synergies expected to obtain with the incorporation of the acquired company into the Company's business. The goodwill recognized is not expected to be deductible for tax purposes until the incorporation.
- e) Refers to the value of goodwill and net assets set forth in the respective individual and consolidated annual financial statements as at December 31, 2020, published on March 6, 2021. For the year 2021, there was the conclusion of the fair value evaluation of assets acquired and liabilities assumed for Santa Celina and São Marcos, which are set forth in this individual and consolidated interim financial information.
- f) In the year 2021, São Marcos and Santa Celina made adjustments in the consideration transferred in the amount of R\$ 19,392 and R\$ 21,493, respectively. The adjustment is within the measurement period and affected directly the goodwill recognized on the business combinations, therefore the total consideration transferred was R\$ 106,925 and R\$ 27,696, respectively.

# 3 Basis of preparation

# 3.1 Statement of compliance (with regard to the standards-of the CPC - Committee of Accounting Pronouncements a-d the IFRS - International Financial Reporting Standards)

The individual interim financial information of the Company for the period ended March 31, 2021 have been prepared in accordance with—CPC 21(R1) - Interim and Consolidated Statement in accordance with—CPC 21(R1) - Interim Statement—and IAS 34 - *Interim Financial Reporting*, issued by the International Accounting Sta—dard Board - IASB and presented in conformity with the standards issued by the Brazilian Securities Commission, applicable to the preparation of the Quarterly—nformation - ITR.

This individual and consolidated interim financial information contains notes selected with the relevant and material corporate information that allows to understand the changes in the financial position and performance of DASA Group since its last individual and consolidated annual financial statements. Thus, this individual and consolidated interim financial information should be read in conjunction with the individual and consolidated financial statements of the Company for the year ended December 31, 2020, published on March 6, 2021.

All material information on the interim financial information, and solely such information, is being evidenced, and corresponds to that used by Management.

The issuance of the individual and consolidated interim financial information was authorized by the Board of Directors in meeting held on May 13, 2021.

### 3.2 Statement of added-value ("DVA")

The presentation of the Statement of Added Value (DVA), individual and consolidated, is required by the Brazilian corporate law and by the accounting practices adopted in Brazil applicable to Publicly-Held Companies.

The International Financial Reporting Standards ("IFRS") do not require the presentation of this statement. Consequently, under the IFRS, this statement is presented as supplementary information, without prejudice to the set of consolidated and individual interim financial statements.

(In thousands of reais, unless otherwise stated)



# 3.3 Functional currency and presentation currency

The individual and consolidated interim financial information is presented in Real (R\$), which is the functional currency of the Company. All the financial statements presented in Reais were rounded to the nearest thousands, except where stated otherwise. For the subsidiaries in Argentina the functional currency is the Argentine Peso (ARS) and for the subsidiary in Uruguay the functional currency is the Uruguayan Peso (UYU) which were translated into Real (R\$).

### Transactions and balances:

Foreign currency transactions are initially recorded at the functional currency's exchange rate in force on the transaction date. Monetary assets and liabilities denominated in foreign currency are translated at the closing exchange rate on the balance sheet date. All differences are reported in the income statement.

Non-monetary items measured at historical cost in foreign currency are translated at the exchange rate in effect on the transaction date. Non-monetary items measured at fair value in foreign currency are translated at the exchange rates in effect on the dates in which the fair value was measured.

The Company monitors the goodwill and any fair value adjustments made in the carrying amounts of assets and liabilities resulting from the acquisition as assets and liabilities of the subsidiaries. Accordingly, these assets and liabilities will be translated into the currency of presentation of the individual and consolidated interim financial information.

# Subsidiaries:

The assets and liabilities of the subsidiaries abroad are translated into reais (R\$) at the closing exchange rate on the date of the respective balance sheet and the corresponding statements of income are translated at the exchange rates in effect on the transaction dates, as well as the cash flow statements. The exchange differences resulting from this translation are accounted for under other comprehensive results.

Any goodwill and any fair value adjustments of the carrying amounts of assets and liabilities resulting from the acquisition are treated as assets and liabilities of the subsidiary abroad and translated at the exchange rate on the presentation date.

### 3.4 Use of estimative and judgments

In the preparation of this individual and consolidated interim financial information, Management used judgments and estimates affecting the adoption of the accounting policies of DASA Group and the reported amounts of assets, liabilities, income and expenses. Actual results may diverge from those estimates.

The estimates and assumptions are reviewed continuously. The reviews of estimates are recognized on prospective basis.

### **Judgments**

Information on judgments made in the adoption of the accounting policies with material effects on the amounts recognized in the individual and consolidated interim financial information is included in the following note—:

• Note 11 - investments: determine if the parent company and its subsidiaries actually hold control over an investee; a–d

Note 16 - lease: determine if a contract contains a lease and classification of commer

• cial lease.

(In thousands of reais, unless otherwise stated)



# **Uncertainties on assumptions and estimates**

Information on uncertainties related to assumptions and estimates as at March 31, 2021 posing material risk of causing a material adjustment in the accounting balances of assets and liabilities in the following periods is included in the following notes:

- Note 2 acquisition of subsidiary (business combinations): fair value of identifiable intangible assets (Noncompetition covenant, Non-contractual relationship with clients and Trademarks) and goodwill, measured on provisional basis when specified;
- Note 7 analysis of Expected credit losses of trade receivables and estimated variable consideration;
- Note 13 review of the useful life of intangible assets and impairment test on intangible assets and goodwill;
- Note 16 definition of the discount rate on lease;
- Note 20 recognition and measurement of provision for tax, social security, labor and civil obligations, principal assumptions about the likelihood and magnitude of outflows of resources;
- Note 23 revenue recognition: estimate of expected variable considerations (disallowances);
- Note 28 recognition of deferred tax assets: availability of future taxable income against which tax losses can be used; and
- Note 30 assumptions used to determine the fair value of financial instruments.

### Measurement of fair value

A series of accounting policies and reporting of DASA Group requires the measurement of fair value for financial and non-financial assets and liabilities.

DASA Group established a control structure related to measurement of fair value. It includes an assessment team that has the general responsibility for reviewing all material measurements of fair value, including Level 3 fair values reporting directly to the Financial Executive Board and Senior Management of DASA Group.

If third-party information, such as prices of brokers or price services, is used to measure the fair value, the assessment team analyzes the evidences obtained from third parties to support the conclusion that such assessments meet the requirements of technical pronouncement CPC / IFRS, including the level in the hierarchy of fair value at which such assessments should be classified.

When measuring fair value of an asset or liability, DASA Group uses market observable data as much as possible. Fair values are classified at different levels in a hierarchy based on the information (*inputs*) used in the valuation techniques, as shown in note 30 - Financial instruments.

DASA Group recognizes the transfers between levels of the hierarchy of fair value at the end of the period of the individual and consolidated interim financial information in which the changes occurred.

(In thousands of reais, unless otherwise stated)



#### 3.5 Measurement basis

The individual and consolidated interim financial information has been prepared based on the historical cost except for the following items recognized in the balance sheets:

- Non-derivative financial instruments measured at fair value through the result;
- Contingent payments assumed in a business combination are measured at fair value; and
- The liabilities for share-based payment transactions settled in cash are measured at fair value.

# 4 Significant accounting policies

DASA Group declares that the accounting practices and policies (including the principles of measurement, recognition and valuation of assets and liabilities), as well as the main accounting judgments and sources of uncertainties on estimates adopted in the preparation of this interim financial information, are consistent with those adopted and disclosed in note 5 to the annual financial statements for the year ended December 31, 2020, published on March 6, 2021.

# 5 Cash and cash equivalents

	Parent Com	Parent Company		ated
	03/31/21	12/31/20	03/31/21	12/31/20
Cash and banks Financial investments (a)	13,076 <u>216,564</u>	31,060 111,985	66,930 <u>684,109</u>	80,339 673,268
	<u>229,640</u>	143,045	<u>751,039</u>	753,607

<sup>(</sup>a) Financial investments are remunerated as percentage of the interest rate of CDI of 100.15% (95.26% as at December 31, 2020), have immediate liquidity and are of very short time, therefore they can be used in accordance with the needs of DASA Group without any penalty.

Bank balances and financial investments have immediate liquidity and are not subject to restrictions or penalties of any nature for use

# **6** Marketable securities

	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
Fixed income investment fund - non-exclusive (a) Committed operation (b)	28 796,599	555 <u>740,361</u>	28 812,289	555 760,261
	<u>796,627</u>	<u>740,916</u>	<u>812,317</u>	<u>760,816</u>

Financial investments are remunerated as percentage of the interest rate of CDI as follows: (a) investment fund at the rate of 89.76% (90.58% as at December 31, 2020) and (b) fixed-income financial investment at the rate of 102.86% (108.40% as at December 31, 2020).



# 7 Trade receivables

	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
Trade receivables:				
Domestic	900,643	978,713	1,823,983	1,843,777
Foreign		<del>_</del>	71,166	53,551
	900,643	978,713	1,895,149	1,897,328
Less:				
Expected credit losses ("impairment") of trade receivables	(36,668)	(45,061)	(97,736)	(106,098)
Expected disallowance variable consideration	(31,950)	(29,043)	(49,399)	(45,344)
	(68,618)	(74,104)	(147,135)	(151,442)
Total trade receivables, net	832,025	904,609	<u>1,748,014</u>	1,745,886
Current	825,339	903,728	1,739,556	1,743,233
Non-current	<u>6,686</u>	881	8,458	2,653
Breakdown of trade receivables:				
To expire	442,461	501,635	1,116,635	1,181,992
Overdue (b)	214.698	193,229	308,023	279,401
Related parties payable	21,514	27,406	-	
Related parties overdue©	13,637	27,127	-	-
Returned checks	1,071	1,032	1,374	3,513
Unbilled agreements (a)	207,262	228,284	<u>469,117</u>	432,422
Total accounts receivable from customers	900,643	<u>978,713</u>	<u>1,895,149</u>	<u>1,897,328</u>

<sup>(</sup>a) The caption unbilled health plans refers to amounts of services rendered and not billed until the closing of the period.

Summary of overdue trade notes (trade notes receivable


(b) ):

	Parent Com	Parent Company		Consolidated	
	<u>03/31/21</u>	12/31/20	03/31/21	12/31/20	
Up to 120	127,075	105,818	186,385	160,190	
121 to 180	15,272	10,252	24,860	13,043	
181 to 360	23,380	29,079	31,658	38,858	
over 360	48,971	48,080	65,120	67,310	
	<u>214,698</u>	<u>193,229</u>	308,023	<u>279,401</u>	

(c) Summary of overdue trade bills (related parties):

	Parent Comp	Parent Company		
	03/31/21	12/31/20		
Up to 120	8,542	25,832		
121 to 180	<u>5,095</u>	<u>1,295</u>		
	<u>13,637</u>	<u>27,127</u>		

DASA Group developed a methodology of assigning ratings to its customers. The history of receipts was analyzed and divided into two groups: rating A and B, respectively: rating–A - customers considered as low risk of default, supported by history of receipts, and rating–B - for which DASA Group analyzes the history of receipts, considering different methodology and percentages for accrual, and analyzes overdue balances by category.





Transaction in the period of expected credit losses ("impairment") of trade receivables:

	<b>Parent Company</b>	Consolidated
Balance as at December 31, 2019	(30,407)	<u>(67,143)</u>
Transactions:		
Expected credit losses of trade receivables	(80,428)	(192,669)
Expected impairment of trade receivables at book value of subsidiaries acquired (a)	-	(48,523)
Reversal of expected credit losses of trade receivables	<u>65,774</u>	202,237
Balance as at December 31, 2020	<u>(45,061)</u>	(106,098)
Transactions:		
Expected credit losses of trade receivables	(4,783)	(11,968)
Reversal of expected credit losses of trade receivables	13,176	20,330
(a) a) Refers to the acquisition of Impar Services Hospitalares (Note 2)		

(a) a) Refers to the acquisition of Ímpar Serviços Hospitalares (Note 2).

Transaction in the period of expected losses for variable consideration:

	Parent Company	Consolidated
Balance as at December 31, 2019	(36,658)	(36,701)
Transactions:		
Expected losses for variable consideration (disallowance)	(10,145)	(40,319)
Expected impairment of trade receivables at book value of subsidiaries acquired (a)	-	(5,985)
Reversal of expected losses for variable consideration (disallowance)	<u>17,760</u>	37,661
Balance as at December 31, 2020	(29,043)	<u>(45,344)</u>
Transactions:		
Expected losses for variable consideration (disallowance)	(2,907)	(4,055)
Balance as at March 31, 2021	(31,950)	(49,399)

<sup>(11)</sup> Refers to the acquisition of İmpar Serviços Hospitalares, as disclosed in the individual and consolidated annual financial statements as at December 31, 2020, published on March 6, 2021.

# 8 Inventories

	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
Domestic direct material (a)	130,291	107,154	286,712	272,576
Imported direct material (a)	7,001	7,704	17,694	7,821
National secondary material (b)	38,223	33,320	47,977	40,682
Consumables	24,676	21,663	33,665	30,205
Inventory held by third parties	<del></del>		8,121	6,516
	<u>200,191</u>	<u>169,841</u>	<u>394,169</u>	357,800

(11) Laboratory and hospital materials for clinical analyses, exams, diagnostic imaging and for use in patients assisted in the hospitals.

(11) Disposable materials used in the process of item (a).

Reduction to net realizable value – In order to reflect the best estimate of loss for DASA Group in relation to its inventories, a reduction to net realizable value was recognized in the individual interim financial information in the amount of R\$ 2,096 (R\$ 2,351 as at December 31, 2020) and in the consolidated in the amount of R\$ 2,815 (R\$ 3,035 as at December 31, 2020) for items without movement for more than 180 days and for those falling due in the same period. The above balances are net of the amount of the provision individually for each category of inventory. The effect of the reduction to net realizable value generated a reversal of R\$ 255 in the parent company and R\$ 220 in the consolidated. This reversal was recognized in the result for 2021.



# 9 Taxes recoverable

<u>-</u>	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
IR/CS (Income and Social contribution taxes recoverable)-withholding at source on billing IR/CS (Income and Social contribution taxes recoverable) –	38,023	-	54,926	-
accelerations of the period	-	-	40,539	-
IRPJ/CSLL (Income and Social contribution taxes recoverable)  – recoverable credit on negative balance PIS (Social Integration Program)/COFINS (Social Security Financing Contribution)/CSLL (Social Contribution on Net	72,071	79,873	115,347	190,596
Profits) – withholding tax on billing withholdings at source on billing	2,255	33	24,573	5,670
Recoverable INSS (National Institute of Social Security)	15,007	12,569	22,399	4,725
Withheld INSS (National Institute of Social Security)	17,843	10,899	46,746	55,723
Others	13,371	13,368	31,958	23,596
	<u>158,570</u>	116,742	<u>336,488</u>	<u>280,310</u>
Current	131,500	<u>116,742</u>	<u>302,810</u>	<u>260,035</u>
Non-current	27,070	<del>_</del>	33,678	20,275

DASA Group intends to consume most of the credits during the fiscal year and the remainder in the following years covered by federal taxes, pursuant to the Brazilian tax rules.

# 10 Other receivables

	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
Advance for acquisition of subsidiary (a)	-	-	310,427	200,000
Payroll	13,980	9,045	40,329	30,601
Credit with former management (b)	6,392	6,036	10,642	10,131
Credit with franchisees I	7,261	7,289	7,493	7,308
Commercial partnerships (d)	8,364	9,786	8,364	9,786
Advances on dividends and interest on equity	· -	· -	4,177	3,087
Dividends and interest on equity payable	56,394	52,042	-	_
Shared services	16,120	5,603	-	-
Rentals	-	-	-	2,024
Others	9,661	<u>8,779</u>	<u>17,187</u>	41,331
	<u>118,172</u>	<u>98,580</u>	<u>398,619</u>	<u>304,268</u>
Current	111,504	89,588	391,438	290,854
Non-current	6,668	<u>8,992</u>	7,181	13,414

<sup>(</sup>a) Advance to sellers of Hospital Leforte Liberdade S.A. in the amount of R\$ 300,427 and Carmo Group R\$ 10,000, as downpayment and principle of payment for the acquisition of the hospital (Note 33).

Credit with former partners of acquired companies, basically related to lawsuits at the time of the former Management lost after the sale of the compan

(b) y.

Advance of commission to franchisee

(c) s.

Assignment of credit with commercial partner

(d) s.

(In thousands of reais, unless otherwise stated)




# 11 Investments

# 11.1 Information on investments in subsidiaries

The main information on the subsidiaries, for the period ended March 31, 2021, is set forth below. This information was adjusted at the percentage of interest held by the Company:

	Parent Company		Consol	Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20	
DASA Real Estate Empreendimentos Imobiliários Ltda.	30,902	32,210	_	-	
CientíficaLab Produtos Laboratoriais e Sistemas Ltda.	151,085	146,063	-	-	
Previl-b - Clinical analyses Ltda.	46,673	44,449	-	_	
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	2,430	2,493	-	-	
Antônio P. Gaspar Laboratórios Ltda.	54,732	47,694	-	-	
Salomão e Zoppi Services Médicos e Participações S.A.	150,620	146,115	-	-	
Laboratório Médico Santa Luzia S.A.	28,495	24,557			
Laboratório Deliberato de Clinical analyses Ltda.	8,356	7,398	-	-	
Insitus Serviços Médicos e Laboratoriais Ltda.	1,076	1,939	-	-	
Valeclin Laboratório de Clinical analyses Ltda.	13,378	12,415	-	-	
Maringá Medicina Nuclear Ltda.	10,748	9,050	-	-	
Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda.	1,086	839	-	-	
Aliança Biotecnologia Ltda.	292	311	-	-	
Laboratório Chromatox Ltda. (b)	14,067	11,403	-	-	
Diagnosis Maipú por Imágenes S.A. (b)	108,968	91,536	-	-	
CPCL-N - Centro de Pesquisas Clínicas Ltda. (b)	1,923	1,802	-	-	
Genia S.A. (b)	2,543	1,107	-	-	
Nobeloy S.A. (b)	4,279	7,352	-	-	
Optiren S.A (b)	9,163	1,624	-	-	
Laboratório Bioclínico MS Ltda. (b)	9,533	6,153	-	-	
Ímpar Serviços Hospitalares S.A. (a) (c)	1,112,894	1,011,089	-	-	
Santa Celina Participações S.A. (c)	57,308	37,471	-	-	
Instituto de Hematologia de S.J.R. Preto LtdI(c)	4,606	3,012	-	-	
Gesto Saúde Sistemas Informatizados, Consultancy					
Médica e Corretora de Seguros Ltda. (i)	3,588		<del>-</del>		
Total investments in subsidiaries	1,828,745	1,648,082	-	-	
Other investments	325	329	5,607	4,332	
Goodwill on acquisition of interest	1,223,156	1,134,791	-	-	
Intangible asset identified in the acquisition of interests	723,781	698,297	-	-	
Cumulative translation adjustment	(76,936)	(72,738)			
Goodwill, intangible assets identified in the acquisition of interests and other investments	1,870,326	1,760,679	<u>5,607</u>	4,332	
Grand total	3,699,071	3,408,761	<u>5,607</u>	4,332	






# 11.2 Information of interest in direct subsidiaries

The following table sets forth a summary of the financial information of subsidiaries at March 31, 2021. The information below was presented at the percentage of interest held by the Company.


	Percentage of interest in paid-in capital	Paid-in capital	Shareholder's equity (Negative shareholder's equity) proportional to the number of shares held	Income for the period
Aa at March 31, 2021				
DASA Real Estate	99.99	25,667	30,902	225
CientíficaLab	99.99	125,177	151,085	5,022
Previlab	99.56	29,613	46,673	3,853
CRMI Petrópolis	70.00	1,080	2,430	5
Laboratório Gaspar	99.99	4,318	54,732	7,038
Salomão e Zoppi	100.00	122,213	150,620	4,505
Laboratório Santa Luzia (a)	100.00	467	28,495	3,938
Laboratório Deliberato	99.99	6,800	8,356	958
Insitus	99.99	1,842	1,076	(863)
Padrão Ribeirão	90.00	51	(2,044)	(514)
Valeclin	100.00	1,100	13,378	2,085
Ruggeri	99.99	6,461	(2,312)	360
Maringá	99.99	12,600	10,748	198
São Camilo	99.99	872	1,086	(253)
Aliança	99.99	1,162	292	(19)
DB Genética (b)	75.00	10	(7,395)	(2,267)
Itulab (b)	99.99	1,153	(7,150)	(496)
Chromatox (b)	100.00	2,766	14,067	2,664
Maipú (b)	100.00	2,599	108,968	655
CPCLIN (b)	80.00	1	1,923	121
Genia (b)	100.00	5,075	2,543	946
Nobeloy (b)	100.00	5,318	4,279	(3,333)
Optiren (b)	100.00	840	9,163	7,221
Bioclinico MS (b)	80.00	5	9,533	3,380
Ímpar (a) (c)	100.00	547,532	1,112,894	1,805
Allbrokers (c)	100.00	6,454	(5,603)	(4,760)
Santa Celina (c)	100.00	9,975	57,308	(7,074)
São Marcos (c)	100.00	20,000	(6,183)	4,792
Hemat (c)	80.00	3,600	4,606	1,594
Grupo Exame (c)	90.00	15,863	(5,643)	9,042
Gesto Saúde (i)	100.00	21,270	3,588	(787)

The following table sets forth a summary of the financial information of subsidiaries as at December 31, 2020. The information below was presented at the percentage of interest held by the Company.





	Percentage of interest in paid-in capital	Paid-in capital	Shareholder's equity (Negative shareholder's equity) proportional to the number of shares held	Income for the fiscal year
At December 31, 2020				
DASA Real Estate	99.99	25,667	32,210	9,446
CientíficaLab	99.99	125,177	146,063	18,448
Previlab	99.56	29,613	44,449	6,860
CRMI Petrópolis	70.00	1,080	2,493	287
Laboratório Gaspar	99.99	4,318	47,694	21,412
Salomão e Zoppi	100.00	122,213	146,115	(3,992)
Laboratório Santa Luzia (a)	100.00	467	24,557	5,119
Laboratório Deliberato	99.99	6,800	7,398	(43)
Insitus	99.99	1,842	1,939	(408)
Padrão Ribeirão	90.00	51	(1,530)	(364)
Valeclin	100.00	1,100	12,415	4,598
Ruggeri	99.99	6,461	(2,672)	4,762
Maringá	99.99	12,600	9,050	239
São Camilo	99.99	872	839	(385)
Aliança	99.99	1,162	311	(311)
DB Genética (b)	75.00	10	(5,129)	(4,354)
Itulab (b)	99.99	1,153	(7,654)	4,479
Chromatox (b)	100.00	2,766	11,403	6,589
Maipú (b)	100.00	2,161	91,536	(6,740)
CPCLIN (b)	80.00	1	1,802	807
Genia - Genética moléculas (b)	100.00			
(h)	100.00	-	-	(228)
Genia (b)	100.00	4,874	1,107	933
Nobeloy (b)	100.00	5,107	7,352	2,471
Optiren (b)	100.00	631	1,624	(10,474)
Bioclinico MS (b)	80.00	5	6,153	4,365
Ímpar (a) (c)	100.00	547,531	1,011,089	(43,377)
Allbrokers (c)	100.00	6,454	(3,843)	(6,997)
Nexa (c) (h)	100.00	-	-	(2,433)
Santa Celina (c)	100.00	9,975	37,471	(15,639)
São Marcos (c)	100.00	20,000	(11,286)	908
Hemat (c)	80.00	3,600	3,012	-
Grupo Exame (c)	90.00	15,863	-	-






# 11.3 Investments transactions / Provision for loss in subsidiaries

The investments transactions as at March 31, 2021 in subsidiaries is shown below:

	Balance as at 12/31/20	Acquisition of subsidiaries	Advance for future capital increase	Transfer between investment and negative shareholder's equity	Equity valuation adjustment (g)	Dividends	Equity accounting	Balance as at 03/31/21
Investments								
DASA Real Estate	32,210	-	-	-	-	(1,533)	225	30,902
CientíficaLab	146,063	-	-	-	-	-	5,022	151,085
Previlab	44,449	-	-	-	-	(1,629)	3,853	46,673
CRMI Petrópolis	2,493	-	-	-	-	(68)	5	2,430
Gaspar	47,694	-	-	-	-	-	7,038	54,732
Salomão e Zoppi	146,115	-	-	-	-	-	4,505	150,620
Santa Luzia (a)	24,557	-	-	-	-	-	3,938	28,495
Deliberato	7,398	-	-	-	-	-	958	8,356
Insitus	1,939	-	-	-	-	(1.122)	(863)	1,076
Valeclin Maringá	12,415 9,050	-	1,500	-	-	(1,122)	2,085 198	13,378 10,748
São Camilo	839	-	500	-	-	-	(253)	1,086
Aliança	311	-	500	(19)	-	-	(233)	292
Chromatox (b)	11,403	_	_	(17)	_	_	2,664	14,067
Maipú (b) (g)	91,536	_	_	_	16,777	_	655	108,968
CPCLIN (b)	1,802	_	_	_	-	_	121	1,923
Genia (b)	1,107	-	-	_	490	_	946	2,543
Nobeloy (b)	7,352	-	-	_	260	-	(3,333)	4,279
Optiren (b)	1,624	-	-	7,221	318	-	,	9,163
Bioclínico MS (b)	6,153	-	-	-	-	-	3,380	9,533
Ímpar (a) (c)	1,011,089	-	100,000	-	-	-	1,805	1,112,894
Santa Celina (c)	37,471	(3,089)	30,000	-	-	-	(7,074)	57,308
Hemat (c)	3,012	-	-	-	-	-	1,594	4,606
Gesto (i)		4,375					<u>(787)</u>	3,588
	1,648,082	<u>1,286</u>	132,000	<u>7,202</u>	17,845	(4,352)	26,682	1,828,745
Provision for loss in subsidiaries:								
Padrão Ribeirão	(1,530)	-	-	-	-	_	(514)	(2,044)
Ruggeri	(2,672)	-	-	-	-	-	360	(2,312)
Aliança	-	-	-	19	-	-	(19)	-
Itulab (b)	(7,654)	-	1,000	-	-	-	(496)	(7,150)
Optiren (b)	-	-	-	(7,221)	-	-	7,221	-
DB Genética (b)	(5,129)	-	-	-	-	-	(2,267)	(7,396)
Allbrokers (c)	(3,843)	-	3,000	-	-	-	(4,760)	(5,603)
São Marcos (c)	(11,286)	311	-	-	-	-	4,792	(6,183)
Grupo Exame (c)	(14,684)	<del>-</del>			<del>-</del>		<u>9,042</u>	(5,642)
	(46,798)	311	4,000	(7,202)			13,359	(36,330)






The investments transactions as at December 31, 2020 in subsidiaries are shown below:

	Balance as at 12/31/20	Acquisition of subsidiaries	Incorporation of subsidiaries	Advance for future capital increase	Transfer between investment and negative shareholder's equity	Equity valuation adjustment (d)	Dividends	Equity accounting	Balance as at 03/31/21
Investments									
DASA Real								0.446	
Estate	22,764	-	-	-	-	-	(2.942)	9,446	32,210
CientíficaLab	130,458	-	-	-	-	-	(2,843)	18,448	146,063
Previlab CRMI	42,594	-	-	-	-	-	(5,005)	6,860	44,449
Petrópolis	2,773	-	-	-	-	-	(567)	287	2,493
Gaspar	29,390	-	-	-	-	-	(3,108)	21,412	47,694
Salomão e	155 502				_		(5.495)	(2.002)	146 115
Zoppi Santa Luzia	155,592	-	-	-	-	-	(5,485)	(3,992)	146,115
(a)	-	(6,638)	-	37,752	(11,676)	-	-	5,119	24,557
Deliberato	8,445	-	-	-	-	-	(1,004)	(43)	7,398
Insitus	1,847	-	-	500	-	-	-	(408)	1,939
Valeclin	10,624	-	-	-	-	-	(2,807)	4,598	12,415
Maringá	3,611	-	-	5,200	-	-	-	239	9,050
São Camilo	424	-	-	800	-	-	-	(385)	839
Aliança DB Genética	-	-	-	300	11	-	-	-	311
(b)	1,302	-	-	-	3,052	-	-	(4,354)	-
Chromatox		(5.000)							
(b) Mainyi (b) (d)	11,752	(6,938)	-	-	-	- 0.000	-	6,589	11,403
Maipú (b) (d) CPCLIN (b)	88,416 995	-	-	-	-	9,860	-	(6,740) 807	91,536
Genia - GM	993	-	-	-	-	-	-	807	1,802
(b)	510	(16)	(266)	-	-	-	-	(228)	-
Genia (b) (d)	425	-	-	-	-	(251)	-	933	1,107
Nobeloy (b)	539			4,799		(457)		2.471	7 252
(d) Optiren (b)	339	6,451	-	4,799	(4,827)	(457)	-	2,471	7,352 1,624
Bioclínico	_	0,431			(4,027)				1,024
MS (b)	4,333	(2,545)	-	-	-	-	-	4,365	6,153
Ímpar (a) (c)	-	756,056	-	335,000	-	-	(36,590)	(43,377)	1,011,089
Nexa (c)	-	18,624	(26,591)	10,400	-	-	-	(2,433)	-
Santa Celina (c)	_	5,871	_	47,239	_	_	_	(15,639)	37,471
São Marcos				.,,235					37,171
(c)	-	(16,194)	-	4,000	11,286	-	-	908	-
Hemat (c)		3,012							3,012
	516,794	<u>757,683</u>	(26,857)	445,990	(2,154)	9,152	(57,409)	4,883	1,648,082
Provision for loss on subsidiaries:									
Santa Luzia									
(a)	(11,676)	-	-	-	11,676	-	-	-	-
Padrão Ribeirão	(1,166)			_	_		_	(364)	(1,530)
Ruggeri	(1,100)	-	-	3,400	-	-	-	4,762	(2,672)
Aliança	(678)	_	_	1,000	(11)	_	_	(311)	(2,072)
Itulab (b)	(13,561)	428	-	1,000	(11)	-	-	4,479	(7,654)
Optiren (b)	(510)	-	-	6,399	4,827	(242)	-	(10,474)	-
DB Genética		(0.055)			(2.052)				(E 100)
(b)	-	(2,077)	-	7.600	(3,052)	-	-	- (( 007)	(5,129)
Allbrokers (c) São Marcos	-	(4,446)	-	7,600	-	-	-	(6,997)	(3,843)
(c)	-	-	-	-	(11,286)	-	-	-	(11,286)
Grupo Exame		(14 (95)						1	(14 (04)
(c)	(38,425)	(14,685) (20,780)	<del>-</del>	19,399	2,154	(242)	<u>-</u>	(8,904)	(14,684) (46,798)
	(LU,T <u>L</u> L)	(40,700)	<del></del>	17,077	<del>2,124</del>	(474)	<del></del>	(0,207)	(70,720)

<sup>(</sup>a) The Company participates indirectly with: 100% of Laboratório de Pesquisas Clínicas e Biomatológicas Ltda., through its direct subsidiary Laboratório Santa Luzia.





- (b) Company acquired by the Company in the year 2019.
- (c) Company acquired by the Company in the year 2020. See details in Note 2.
- (d) Effect on the translation of financial statements of subsidiaries abroad and adoption of CPC 42 / IAS 29 Hyperinflation.
- (e) Company incorporated by the Company in the year 2020.
- (f) Company acquired by the Company in the first quarter of 2021. See details in Note 2.

# 12 Property, plant and equipment


Real estate properties         4         8,304 (796)         7,508 (7,590)         7,590           Improvements in third party properties         10         848,733 (573,932)         274,801 (286,017)         286,017           Improvements in own properties         10         4,066 (3,117) (949)         1,052           Appliances and equipment         12         1,254,093 (694,409) (595,684)         587,135           Furniture and utensils         10         118,606 (72,222) (72,222) (76,333) (78,190)         78,190           Facilities         10         164,560 (88,227) (76,333) (73,333) (73,440)           IT equipment         20         244,798 (165,815) (78,983) (74,440)           Vehicles         20         2,165 (2,000) (165) (79,983) (79,983) (79,440)           Vehicles         20         2,165 (2,000) (165) (79,983) (79,983) (79,440)           Library         10         196 (194) (22) (20,000) (165) (180) (180) (180) (194) (
Improvements in third party properties   10
Improvements in own properties
Improvements in own properties
Appliances and equipment 12 1,254,093 (694,409) 559,684 587,135  Furniture and utensils 10 118,606 (72,222) 46,384 48,445  Facilities 10 164,560 (88,227) 76,333 78,190  IT equipment 20 244,798 (165,815) 78,983 77,440  Vehicles 20 2,165 (2,000) 165 189  Library 10 196 (194) 2 2 2  Lands - 180 - 180 180  Fixed assets in progress - 20,450 - 20,450 2,252  Provision for impairment losses - (4,817) - (4,817)  2,661,334 (1,600,712) 1,060,622 1,083,675   Consolidated 03/31/21 12/31/20
Facilities 10 164,560 (88,227) 76,333 78,190 IT equipment 20 244,798 (165,815) 78,983 77,440 Vehicles 20 2,165 (2,000) 165 189 Library 10 196 (194) 2 2 2 Lands - 180 - 180 180 Fixed assets in progress - 20,450 - 20,450 2,252 Provision for impairment losses - (4,817) - (4,817)
Tr equipment   20   244,798   (165,815)   78,983   77,440   Vehicles   20   2,165   (2,000)   165   189   Library   10   196   (194)   2   2   2   2   2   2   2   2   2
Vehicles         20         2,165         (2,000)         165         189           Library         10         196         (194)         2         2           Lands         -         180         -         180         180           Fixed assets in progress         -         20,450         -         20,450         2,252           Provision for impairment losses         -         (4,817)         -         (4,817)         (4,817)           Consolidated 03/31/21         1,060,622         1,083,675
Library 10 196 (194) 2 2 2 Lands - 180 - 180 180  Fixed assets in progress - 20,450 - 20,450 2,252  Provision for impairment losses - (4,817) - (4,817) (4,817)  Consolidated 03/31/21 12/31/20  Cost Accumulated Net Net
Lands - 180 - 180 180  Fixed assets in progress - 20,450 - 20,450 2,252  Provision for impairment losses - (4,817) - (4,817) (4,817)  - 2,661,334 (1,600,712) 1,060,622 1,083,675   Consolidated 03/31/21 12/31/20  Cost Accumulated Net Net
Fixed assets in progress - 20,450 - 20,450 2,252 Provision for impairment losses - (4,817) - (4,817) (4,817)  2,661,334 (1,600,712) 1,060,622 1,083,675   Consolidated 03/31/21 12/31/20  Cost Accumulated Net Net
Provision for impairment losses - (4,817) - (4,817) (4,817)  2,661,334 (1,600,712) 1,060,622 1,083,675   Consolidated 03/31/21 12/31/20  Accumulated Net Net
2,661,334 (1,600,712) 1,060,622 1,083,675  Consolidated 03/31/21 12/31/20  Accumulated Net Net
Consolidated 03/31/21 12/31/20  Cost Accumulated Not Not
03/31/21 12/31/20  Cost Accumulated Not Not
Cost
Real estate properties 4 10,206 (3,259) 6,947 34,043
Improvements in third party properties 10 2,242,786 (989,456) 1,253,330 1,135,944
Improvements in own properties $10$ 8,646 $(7,696)$ 950 $(194)$
Appliances and equipment 12 2,020,546 (1,096,749) 923,797 1,021,455
Furniture and utensils 10 232,012 (121,804) 110,208 94,684
Facilities 10 218,541 (110,005) 108,536 90,528
IT equipment 20 355,102 (235,945) 119,157 122,459
Vehicles 20 5,044 (4,182) 862 935
Library 10 202 (200) 2 3
Lands - 4,714 - 4,714 4,714
Fixed assets in progress - 126,660 - 126,660 109,200
Provision for impairment losses - $(4,817)$ - $(4,817)$ $(4,817)$

5,219,642

(2,569,296)

2,650,346


2,608,954





Parent Company	Balance as at 01/01/20	Accretion from Incorporation of net subsidiaries	Additions	Write- offs	Transf.	Depreciation	Balance as at 12/31/20	Additions (a)	Write- off	Transf.	Depreciation	Balance as at 03/31/21
Real estate properties	140	-	-	(71,473)	78,953	(30)	7,590	_	-	_	(82)	7,508
Improvements in third party										4,480	(15,695)	274,801
properties	277,881	39	-	(303)	73,193	(64,793)	286,017	-	(1)	· ·	` ' '	· · · · · ·
Improvements in own properties	1,458	-	-	-	-	(406)	1,052	-	-	(1)	(102)	949
Appliances and equipment	529,707	11	-	(82)	168,454	(110,955)	587,135	-	(6)	3,204	(30,649)	559,684
Furniture and utensils	47,321	16	-	(311)	10,394	(8,975)	48,445	-	(112)	396	(2,345)	46,384
Facilities	67,297	14	_	(19)	23,932	(13,034)	78,190	-	(5)	1,265	(3,117)	76,333
IT equipment	48,544	488	-	(426)	47,240	(18,406)	77,440	-	(6)	7,350	(5,801)	78,983
Vehicles	312	-	_	(8)	_	(115)	189	-	-	_	(24)	165
Library	9	-	_	-	-	(7)	2	-	_	_	-	2
Lands	180	-	_	_	-	-	180	_	_	_	-	180
Fixed assets in progress	107,097	-	281,011	_	(385,856)	_	2,252	42,957	_	(24,759)	-	20,450
Provision for impairment loss	(4,817)	-	-	-	-	-	(4,817)		-	-	-	(4,817)
	1,075,129	<u>568</u>	281,011	(72,622)	<u>16,310</u>	(216,721)	1,083,675	42,957	(130)	(8,065)	(57,815)	1,060,622

<sup>(</sup>a) Refers mainly to investments in progress in devices, equipment and leasehold improvements. Of total accretions, R\$ 23,046 had no cash effect in the period.





Consolidated	Balance as at 01/01/20	Acquisitions of net subsidiaries (a)	Additions	Write- offs	Net exchange rate variation	Net inflation (c) (d)	Transf. (b)	Depreciation	Balance as at 12/31/20	Acquisitions of net subsidiaries (a)	Additions (e)	Write- offs	Net exchange rate variation	Net inflation (c)(d)	Transf. (b)	Depreciation	Balance as at 03/31/21
															(20,12		
Real estate properties	15,349	9,411	3,930	(72,309)	(3,780)	2,996	78,936	(490)	34,043	-	9,072	-	(1,181)	3,368	9)	(228)	24,945
Improvements in third party																	
properties	357,751	655,903	83,828	(502)	(10,200)	8,877	166,633	(126,346)	1,135,944	12,344	4,302	(1)	2,725	9,978	31,241	(30,516)	1,166,017
Improvements in own																	
properties	472	13	-	(13)	303	(266)	-	(703)	(194)	-	-	-	299	(299)	1,246	(102)	950
Appliances and equipment	609,966	345,101	99,695	440	2,163	(493)	150,290	(185,707)	1,021,455	442	11,496	(501)	(927)	(554)	3,752	(50,385)	984,778
Furniture and utensils	54,870	41,338	8,330	(521)	(277)	56	6,705	(15,817)	94,684	200	1,374	(137)	824	63	1,591	(4,257)	94,342
Facilities	76,182	1,124	5,753	(34)	(972)	170	26,171	(17,866)	90,528	19,328	404	(295)	(731)	191	18,710	(3,915)	124,220
IT equipment	51,813	4,086	18,712	(601)	(241)	(164)	76,851	(27,997)	122,459	313	2,356	(69)	(650)	(188)	13,642	(10,190)	127,673
Vehicles	808	839	75	(339)	2	(13)	-	(437)	935	-	-	(48)	98	(15)	(8)	(100)	862
Library	10	-	-	-	-	-	-	(7)	3	-	-	-	-	-	(1)	-	2
Lands	3,389	2,000	-	(675)	-	-	-	-	4,714	-	-	-	-	-	-	-	4,714
															(57,15		
Fixed assets in progress	117,303	157,089	333,346	(5,011)	-	-	(493,527)	-	109,200	-	74,640	(22)	(1)	-	7)	-	126,660
Provision for impairment loss	(4,817)	-	-	-	-	-	-	-	(4,817)	-	-	-	-	-	-	-	(4,817)
	1.283.096	1.216.904	553,669	(79,565)	(13,002)	11.163	12,059	(375,370)	2,608,954	32,627	103.644	(1.073)	456	12,544	(7.113)	(99,693)	2,650,346

<sup>(</sup>a) Companies acquired by DASA Group (Note 2)

The accretions of accumulated depreciation shown in changes in fixed assets were recorded part under the caption general and administrative expenses and part under the caption costs of services provided, and this allocation is linked to the end use of each asset.

Every year, DASA Group evaluates its assets and it did not identify, in the last annual valuation, indicators of non-recoverability.

<sup>(</sup>b) Expenses incurred by DASA Group classified as fixed assets in progress during the period of construction and installation, are transferred to specific group under the caption fixed assets when available for use, after conclusion of the project, the depreciation of related assets begin.

<sup>(</sup>c) Adoption of CPC 42 / IAS 29 - Hyperinflation. Updates are made by applying a general price index between the acquisition date or occurrence and March 31, 2021.

<sup>(</sup>d) In consolidation, the fixed assets of operations abroad are translated into reais (R\$) at the exchange rate on the balance sheet date.

<sup>(</sup>e) Of total accretions, R\$ 28,772 had no cash effect in the period.



## 13 Intangible assets

			Parent Company 03/31/21		12/31/20
	Useful life in years	Cost	Accumulated amortization	Net	Net
Acquisition of interest -Goodwill		2,053,554	-	2,053,554	2,053,554
Intangible Assets identified in acquisition of equity interest:					
Intangible Assets Trademarks	3,3	309,854	(92,460)	217,394	219,963
Established customer relationships	5	72,613	(35,174)	37,439	38,094
Software	20	7,680	· · · · · · · ·	7,680	-
Other intangible assets:					
IT Systems	20	724,672	(432,989)	291,683	276,253
Right of use of commercial area	20	6,523	(3,314)	3,209	3,474
Trademarks and patents	33	96	(68)	28	29
Customer exclusivity agreement Goodwill	10 7	13,670	(10,290)	3,380	3,592
Intangible Assets in progress	/	1,243 20,019	(175)	1,068 20,019	1,025 20,019
intangible Assets in progress		20,017	<u></u>	20,017	20,017
		3,209,924	(574,470)	<u>2,635,454</u>	2,616,003
		•	Consolidated 03/31/21		12/31/20
			03/31/21		12/31/20
	Useful life in				
		Cost	Accumulated	Not	Not
	years	Cost	Accumulated amortization	Net	Net
		Cost		Net	Net
Acquisition of interest -Goodwill		3,324,171		Net 3,324,171	Net 3,181,278
Intangible Assets identified in					
Intangible Assets identified in acquisition of ownership interest:	years	3,324,171	amortization	3,324,171	3,181,278
Intangible Assets identified in acquisition of ownership interest: Trademarks	years	3,324,171 798,487	amortization - (128,677)	3,324,171 669,810	3,181,278 666,193
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client	3,3 5	3,324,171 798,487 353,719	(128,677) (96,256)	3,324,171 669,810 257,463	3,181,278 666,193 232,226
Intangible Assets identified in acquisition of ownership interest: Trademarks	years	3,324,171 798,487	amortization - (128,677)	3,324,171 669,810	3,181,278 666,193
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software	3,3 5 3-5	3,324,171 798,487 353,719 20,277	(128,677) (96,256)	3,324,171 669,810 257,463 8,724	3,181,278 666,193 232,226 11,216
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets:	3,3 5 3-5 20	3,324,171 798,487 353,719 20,277 11,122	(128,677) (96,256) (11,553)	3,324,171 669,810 257,463 8,724 11,122	3,181,278 666,193 232,226 11,216 7,680
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets: IT Systems	3,3 5 3-5	3,324,171 798,487 353,719 20,277 11,122 809,710	(128,677) (96,256) (11,553)	3,324,171 669,810 257,463 8,724 11,122 322,943	3,181,278 666,193 232,226 11,216 7,680 308,513
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets: IT Systems Right of use of commercial area Trademarks and patents	3,3 5 3-5 20	3,324,171 798,487 353,719 20,277 11,122	(128,677) (96,256) (11,553)	3,324,171 669,810 257,463 8,724 11,122	3,181,278 666,193 232,226 11,216 7,680
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets: IT Systems Right of use of commercial area	3,3 5 3-5 20 20 20	3,324,171 798,487 353,719 20,277 11,122 809,710 12,362	(128,677) (96,256) (11,553) (486,767) (3,315)	3,324,171 669,810 257,463 8,724 11,122 322,943 9,047	3,181,278 666,193 232,226 11,216 7,680 308,513 9,313
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets: IT Systems Right of use of commercial area Trademarks and patents Customer exclusivity agreement Goodwill	3,3 5 3-5 20 20 20 33	3,324,171  798,487 353,719 20,277 11,122  809,710 12,362 165 43,076 6,666	(128,677) (96,256) (11,553) (486,767) (3,315) (164)	3,324,171  669,810 257,463 8,724 11,122  322,943 9,047 1 24,484 6,401	3,181,278  666,193 232,226 11,216 7,680  308,513 9,313 3 26,534 6,358
Intangible Assets identified in acquisition of ownership interest: Trademarks Non contractual relationship with client Non-competition agreement Software  Other intangible assets: IT Systems Right of use of commercial area Trademarks and patents Customer exclusivity agreement	3,3 5 3-5 20 20 20 33 10	3,324,171  798,487 353,719 20,277 11,122  809,710 12,362 165 43,076	(128,677) (96,256) (11,553) (486,767) (3,315) (164) (18,592)	3,324,171  669,810 257,463 8,724 11,122  322,943 9,047 1 24,484	3,181,278 666,193 232,226 11,216 7,680 308,513 9,313 3 26,534

(In thousands of reais, unless otherwise stated)



Parent Company	Balance as at 01/01/20	Accretion from Incorporatio n of net subsidiaries	Additions	Write-offs	Transfer.	Amortization	Balance as at 12/31/20	Additions (a)	Write-offs	Transfer.	Amortization	Balance as at 03/31/21
Acquisition of interest - Goodwill	2,026,422	27,132	-	-	-	-	2,053,554	-	-	-	-	2,053,554
	2,026,422	27,132	-	-	-	-	2,053,554	-	-	-	-	2,053,554
Trademarks Non contractual relationship with client Added value of assets Software	230,240 41,355 14,354	7,680	- - - -	- - - -	(19,924)	(10,277) (3,261) (2,110)	219,963 38,094 -	- - - -	- - - -	385 7,680	(2,569) (655) (385)	217,394 37,439 - 7,680
	285,949	7,680	-	-	(19,924)	(15,648)	258,057	-	-	8,065	(3,609)	262,513
IT Systems Right of use of commercial area Trademarks and patents Exclusivity agreement with customers Goodwill Intangible Assets in progress	193,515 4,538 32 4,438 1,148 4,547	17,521	148,979	(75)	154,642	(71,833) (1,064) (3) (846) (123)	276,253 3,474 29 3,592 1,025 20,019	37,488	- - - - -	37,413 - - 75 (37,488)	(21,983) (265) (1) (212) (32)	291,683 3,209 28 3,380 1,068 20,019
	208,218	17,525	148,979	(75)	3,614	(73,869)	304,392	37,488			(22,493)	319,387
	2,520,589	52,337	148,979	<u>(75)</u>	(16,310)	(89,517)	2,616,003	<u>37,488</u>		8,065	(26,102)	2,635,454

<sup>(</sup>a) Refers mainly to investments in development of systems.

(In thousands of reais, unless otherwise stated)



Consolidated	Balance as at 01/01/20	Acquisitions of net subsidiaries (a)	Additions	Write- offs	Net exchange rate variation (d)	Net inflation (c)	Transf. (b)	Amortization	Balance as at 12/31/20	Acquisitions of net subsidiaries. (a)	Additions (f)	Write-offs	Net exchange rate variation (d)	Net inflation (c)	Transf. (b)	Amortization	Balance as at 03/31/21
Acquisition of interest - Goodwill	2,995,552	199,013	-	-	11,280	-	(24,567)	-	3,181,278	154,833	-	-	349	-	(12,289)	-	3,324,171
	2,995,552	199,013	_	-	11,280	-	(24,567)	-	3,181,278	154,833	-	-	349	-	(12,289)	-	3,324,171
Trademarks	585,053	95,467	_	_	2,261	_	6,622	(23,210)	666,193	9,958		_	(424)	_	(112)	(5,805)	669,810
Non contractual relationship with client	195,182	50,798	_	_	3,311	_	9,837	(26,902)	232,226	22,799	_	_		_	10,922	(6,576)	257,463
Added value of assets	18,333	-	_	_		_	(15,628)	(2,705)		-	_	_	(1,,,,,,,,	_	483	(483)	-
Noncompetition agreement	9,397	_	_	-	1,211	-	6,693	(6,085)	11,216	-	-		(641)	_	(330)	(1,521)	8,724
Software	-	7,680	-	-	-	-	-	-	7,680	3,442	-	-	-	-	-	-	11,122
	807,965	153,945	-	-	6,783	-	7,524	(58,902)	917,315	36,199	-	-	(2,973)	-	10,963	(14,385)	947,119
IT Systems	202,243	38,338	14,176	(1,269)	(1,400)	145	138,096	(81,816)	308,513	26	4,235	(381)	(4,643)	170	39,166	(24,143)	322,943
Right of use of commercial area	4,538	-	13,590	(7,751)	-	-	-	(1,064)	9,313	-	-	-	-	-	-	(266)	9,047
Trademarks and patents	3	6	-	-	-	-	8	(14)	3	12	-	-	-	-	(12)	(2)	1
Exclusivity agreement with customers	6,201	-	25,036	-	62	-	867	(5,632)	26,534	-	175	-	(759)	-	-	(1,466)	24,484
Goodwill	1,148	5,333	-	-	-	-	-	(123)	6,358	-	-	-	-	-	75	(32)	6,401
Intangible Assets in progress	4,547	-	149,262	-	-	-	(133,790)	-	20,019	-	37,488	-	-	-	(30,790)	-	26,717
	218,680	43,677	202,064	(9,020)	(1,338)	145	5,181	(88,649)	370,740	38	41,898	(381)	(5,402)	170	8,439	(25,909)	389,593
	4,022,197	396,635	202,064	(9,020)	16,725	145	(11,862)	(147,551)	4,469,333	191,070	41,898	(381)	(8,026)	170	7,133	(40,294)	4,660,883


<sup>(</sup>a) Companies acquired by DASA Group. Of the total goodwill of R\$ 154,833, R\$ 113,948 refers to companies acquired in the year 2021 and R\$ 40,885 results from adjustments within the period of remeasurement (Note 2).

<sup>(</sup>b) Costs incurred classified as intangible assets in progress during the period of development are transferred to specific caption in the group of intangible assets when available for use. The amount of the reclassification in the consolidated refers to expenses with software, reclassified from fixed assets in progress to fixed assets. There was also the reclassification of the appreciation, which should be disclosed in accordance with the assets to which they refer. It was transferred from Intangible Assets to Property, plant and equipment under the caption fixtures and equipment.

<sup>(</sup>c) Adoption of CPC 42 / IAS 29 - Hyperinflation. Updates are made by applying a general price index between the acquisition date or occurrence and March 31, 2021.

<sup>(</sup>d) In consolidation, the intangible assets of operations abroad are translated into reais (R\$) at the exchange rate on the balance sheet date.

<sup>(</sup>e) Refers mainly to investments in development of systems.





The additions to accumulated amortization, presented in the transaction, were recorded part under the caption general and administrative expenses and part under the caption costs of services provided.

### **Impairment test**


The impairment test on assets with indefinite useful life is conducted one a year, or when there is indication of impairment of any of the Cash Generating Units ("CGU") to which they are allocated. For the three-month period ended March 31, 2021, Management concluded that there is no indication of impairment of its CGUs. The last impairment test of intangible assets was conducted for the year ended December 31, 2020, as set forth in the respective individual and consolidated annual financial statements, disclosed on March 6, 2021.

## 14 Trade payables

	Parent Com	Consolidated		
	03/31/21	12/31/20	03/31/21	12/31/20
Domestic Suppliers Foreign suppliers Specialized medical services	407,549 37,795 <u>54,477</u>	474,316 25,479 49,859	752,641 43,817 <u>68,408</u>	814,590 31,438 <u>62,608</u>
	499,821	549,654	864,866	908,636
Current Non-current	486,109 13,712	535,942 13,712	849,509 15,357	893,175 15,461

## 15 Loans and financing

		<u>_</u>	Parent Con	mpany	Consolic	lated
Proceed	Average charges	Final maturity	03/31/21	12/31/20	03/31/21	<u>12/31/20</u>
BNDES - FINAME PSI (i) (ii)	6% per year, 9.5% per year, and TJLP +	15/12/2024	3,966	4,249	3,966	4,249
FINEP - (iv)	TJLP + 3%	09/15/26	20,901	21,851	20.901	21,851
` /	CDI +	07/15/20	20,701	21,031	20,701	21,031
Promissory Notes (i)	1.95%	04/07/2022	1,156,025	648,549	1,156,025	648,549
Banks - GSM - Nacional	6.46% per year 9.38% per	05/15/2025	-	-	65,631	72,809
Banks - GRUPO EXAME - Nacional	year and 0.75% per					
	month	10/21/2025	-	-	23,529	25,588
Banks - Maipú - Internacional (iii) (v)	CDI + 6% per year USD/EUR	10/10/2025	-	-	19,644	22,015
Banks - Ímpar - Internacional	O + 3.76% to 4.45%	10/31/2024				
	per year		-	-	357,936	380,515
FINAME - Ímpar (vi)	8.92% per year	08/31/2022	-	-	2,399	2,930
Others	-	-	-	-	17,642	20,212





			Parent Con	mpany	Consoli	dated
Average Proceed charges i		Final maturity	03/31/21	12/31/20	03/31/21	12/31/20
Leasing:						
Financial lease	IGPM	06/22/2021	297	742	297	742
Financial lease - Ímpar	15.85% per year	03/31/2024	-	-	1,460	2,249
Financial lease - GSM	14.1% per year	04/30/2022			8	<u> 106</u>
			<u>1,181,189</u>	675,391	1,669,438	<u>1,201,815</u>
Current			_ 547,218	46,211	655,343	200,194
Non-current			633,971	<u>629,180</u>	1,014,095	1,001,621

The loans and financing transaction is as follow:

	Parent Company	Consolidated
Balance as at December 31, 2019	90,559	108,809
Fund raising	648,485	796,942
Interest incurred and exchange rate variation	24,263	114,322
Interest paid	(10,861)	(50,672)
Amortization principal	(77,055)	(338,866)
Acquisitions of subsidiaries		571,280
Balance as at December 31, 2020	675,391	<u>1,201,815</u>
Fund raising	500,000	500,000
Interest incurred and exchange rate variation	7,728	29,535
Interest paid	(234)	(4,735)
Principal amortization	(1,696)	(57,177)
Balance as at March 31, 2021	1,181,189	1,669,438

### Collateral for loans and financing:

- (i) Promissory Note of 100% of the amount of the agreement on behalf of the Company
- (ii) Financed asset
- (iii) Real estates, guarantee, assignment of credit rights
- (iv) Letter of guarantee
- (v) Mortgage
- (vi) Collateral

Except for the promissory notes, as detailed below in comment (a) bank loan and financing agreements do not contain restrictive covenants. Bank loans and financing, classified in current liability and non-current liability, following the contractual maturity terms will be amortized as shown in note 30 - Financial instruments in liquidity risk.

#### **Promissory Notes**

(i) On December 5, 2017, the Company's Board of Directors approved the 5<sup>th</sup> issuance, by the Company, of 300 promissory notes, in 3 (three) series, in physical form, with unit nominal value of R\$ 1,000 (one million reais) ("Promissory Notes"), with total amount of R\$ 300,000 on the issuance date, that is, December 28, 2017, for placement through public offering of distribution with restricted placement efforts, under the terms of CVM Instruction No. 476, of January 16, 2009, as amended. On December 28, 2017 the public offering of distribution was concluded.

The issuance was made in 3 series, as follows (i) 200 Promissory Notes of the first series, (ii) 50 Promissory Notes of the second series and (iii) 50 Promissory Notes of the third series. The term (i) of the Promissory Notes of the first series is of up to 365 days from the issuance date, (ii) of the Promissory Notes of the second series is of up to 730 days from the issuance date and (iii) of the Promissory Notes of the third series is of up to 1,095 days from the issuance date.

(In thousands of reais, unless otherwise stated)



(ii) On March 23, 2020, the Company's Board of Directors approved the 6<sup>th</sup> issuance, by the Company, of 130 promissory notes, in 4 (four) series, in physical form, with unit nominal value of R\$ 5,000 (five million reais) ("Promissory Notes"), with total amount of R\$ 650,000 on the issuance date, that is, April 7, 2020, for placement through public offering of distribution with restricted placement efforts, under the terms of CVM Instruction No. 476, of January 16, 2009, as amended. On April 7, 2020 the public offering of distribution was concluded.

The issuance was made in 4 series, as follows (i) 4 Promissory Notes of the first series, (ii) 4 Promissory Notes of the second series, (iii) 4 Promissory Notes of the third series, and (iv) 118 Promissory Notes of the fourth series. The term (i) of the Promissory Notes of the first series is of up to 185 days from the issuance date, (ii) of the Promissory Notes of the second series is of up to 370 days from the issuance date, (iii) of the Promissory Notes of the third series is of up to 550 days from the issuance date, and (iv) of the Promissory Notes of the fourth series is of up to 730 days from the issuance date.

The operations of promissory notes contracted by the Company require the compliance with restrictive financial covenants, under penalty of early maturity of the related debts. The noncompliance with the obligations or restrictions for two consecutive quarters may cause the early maturity of the related debts and default in relation to other contractual obligations (cross-default), depending on each loan and financing agreement.

iii) On March 8, 2021, the Company's Board of Directors approved the 7<sup>th</sup> issuance, by the Company, of 500 promissory notes, in single series, in physical form, with unit nominal value of R\$ 1,000 (one million reais) ("Promissory Notes"), with total amount of R\$ 500,000 on the issuance date, that is, March 11, 2021, for placement through public offering of distribution with restricted placement efforts, under the terms of CVM Instruction No. 476, of January 16, 2009, as amended. On March 11, 2021 the public offering of distribution was concluded. The term of the promissory notes is of 180 days from the issuance date

The Promissory Notes contain clauses establishing the maximum levels of indebtedness and leverage, based on the consolidated interim financial information:

1- Net debt / EBITDA - maximum index
2- EBITDA / Financial result - minimum index
1.50

For purposes of reading the references above, the following definitions have been considered:

Financial net debt for covenant purposes: is calculated by: (i) the sum of all Company's consolidated debts to individuals and / or legal entities, limited to: (a) loans and financing with third parties; (b) debts arising from issuance of fixed income securities, in circulation in the local and / or international capital markets; (c) net balance of derivative transactions (that is, liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; minus (ii) the sum (a) of the amount available in the Company's cash; (b) the net balances of the Company's current bank accounts; and (c) the balances of the Company's financial investments.

Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) for covenant purposes: it's a non-accounting measure prepared by the Company for the 4 (four) immediately preceding quarters, and corresponds to the Company's net income before net financial expenses, income tax, depreciation and amortization, adjusted by the exclusion of certain unusual expenses such as share-based payment plan (for some contracts, expenses with share-based plan are not foreseen). In case of acquisition(s), it will be considered, for purposes of calculating EBITDA, the generated EBITDA (s) in the period of 12 (twelve) months immediately before the end of each quarter by the acquired company (ies). Adjusted EBITDA is not a measure recognized in accordance with the accounting practices adopted in Brazil or IFRS, does not have a standard meaning and may not be comparable with the Adjusted EBITDA prepared by other companies. The Adjusted EBITDA presents limitations that may impair its use as measure of profitability, and should not be considered in isolation or as alternative to our net profit, operating profit or operating cash flow, base of distribution of dividends or indicator of liquidity, operating performance or payment capacity. The Company uses the Adjusted EBITDA to assess its result without the influence and effects of the items mentioned above.

Financial result for covenant purposes: represents the difference between the Company's financial income and financial expense for the 4 (four) quarters immediately prior to the current quarter, relating exclusively: (i) to the financial expenses related to the Company's consolidated debts before individuals and / or legal entities, limited to (a) loans and financing with third parties; (b) debts arising from issuance of fixed income securities, in circulation in the local and / or international capital markets; (c) net balance of derivative transactions (that is, liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; and (ii) financial income referring to (a) the amount available in the Company's cash; (b) net balances of the Company's current bank accounts; and (c) balances of the Company's financial investments.

(In thousands of reais, unless otherwise stated)



### 16 Leases payables

### **Domestic financial lease**

DASA Group is lessee of assets recorded in property, plant and equipment, object of agreements which are: with call option, without renewal option, have contingent payments, and have no restrictive covenants, related to Dividends and interest on own capital or additional debt. The details of these agreements are set forth in Note 15.


### Asset of right of use and lease liabilities

DASA Group has real estate lease operations such as: service units, warehouses, administrative headquarters and operational technical centers. The average term of the agreements ranges from 5 to 10 years, but they are traded individually.

				Parent	Company			
	Balance as at 12/31/20	Addition (c)	Amortization	Interest (a)	Payments	Revaluatio n (b)	Transfer	Balance as at 03/31/21
Assets								
Right of use	<u>796,876</u>	16,881	(35,556)			47,924		826,125
Liabilities Commercial leasing rentals Provision for demobilization cost	806,258	16,881	-	20,866	(53,881)	47,924	-	838,048
- non-current	51,225			=	<u>-</u>	=	=	51,225
	<u>857,483</u>	<u>16,881</u>		20,866	(53,881)	<u>47,924</u>		889,273
Current Non-current	294,843 562,640	<u>16,881</u>		20,866	(53,881)	47,924 ————————————————————————————————————	52,700 (52,700)	379,333 509,940

Assets	Balance as at 12/31/19	Addition (c)	Amortization	Interest (a)	Payments	Revaluation (b)	Transfer	Balance as at 12/31/20
Right of use	<u>881,965</u>	<u>5,672</u>	(155,636)			<u>64,875</u>		796,876
Liabilities Commercial leasing rentals Provision for demobilization cost -	857,592	5,672	-	85,590	(207,471)	64,875	-	806,258
non-current	<u>51,225</u>			Ξ	=	Ξ		51,225
	908,817	<u>5,672</u>		85,590	(207,471)	64,875		<u>857,483</u>
Current Non-current	125,820 782,997	<u>5,672</u>	<u> </u>	<u>-</u> 85,590	(207,471) ————————————————————————————————————	<u>64,875</u>	305,947 (305,947)	294,843 562,640

**Parent Company** 





		Consolidated							
A	Balance as at 12/31/20	Acquisition of subsidiaries	Addition (c)	Amortization	Interest (a)	Payments	Revaluation (b)	Transfer	Balance as at 03/31/21
Assets Right of use	1,384,934	2,244	<u>59,474</u>	(71,064)			100,833		1,476,421
Liabilities Commercial leasing rentals Provision for demobilization cost	1,431,472	2,244	59,474	-	44,448	(100,541)	100,833	-	1,537,930
- non-current	54,041								54,041
	1,485,513	<u>2,244</u>	59,474		44,448	(100,541)	100,833		1,591,971
Current Non-current	427,238 1,058,275	2,244	39,179 20,295		44,448	(100,541)	97,030 <u>3,803</u>	(6,338) <u>6,338</u>	503,260 1,088,711

	Consolidated								
	Balance as at 12/31/19	Acquisition of subsidiaries	Addition (c)	Amortization	Interest (a)	Payments	Revaluation (b)	Transfer	Balance as at 12/31/20
Assets Right of use	888,042	517,671	124,345	(242,665)			97,541		1,384,934
Liabilities Commercial leasing rentals Provision for demobilization cost - non-current	863,618 51,807	540,828	113,290 <u>1,710</u>	- 	129,239	(325,049)	109,546 524	- 	1,431,472 <u>54,041</u>
	915,425	540,828	115,000		129,239	(325,049)	110,070		1,485,513
Current Non-current	127,160 788,265	81,508 459,320	64,755 50,245	<del>-</del>	<u>-</u> 129,239	(325,049)	69,218 40,852	409,646 (409,646)	427,238 1,058,275

(a) Interest is recorded in the result under the caption of financial expenses, at discount rate, considering the average fund raising in the market, as shown below:


Terms of the agreements	Rate
2 years	7.18%
4 years	7.44%
5 years	7.47%
10 years	8.25%
Weighted average	7.58%

- (b) The remeasurement is originated by changes in future lease payments resulting from change of rate used to determine these payments (IGP-M). DASA Group remeasured the lease liability to reflect these reviewed payments. There was no change in the lease term and there was no need to review the discount rate. The impact of the remeasurement was R\$ 47,924 in the Parent Company and R\$ 100,833 in the consolidated, without immediate effect on the result and without effect on the cash flow statements.
- (c) The impact of accretion at Parent Company and Consolidated does not have an immediate effect on the result and cash flow statements.

Maturities of non-current installments as at March 31, 2021 are shown below:

	<b>Parent Company</b>	Consolidated
Until April, 2022	138,518	259,268
2023	131,722	239,620
2024	122,864	216,676
after 2025	<u>116,836</u>	373,147
	509,940	1,088,711

Given that DASA Group's taxation regime is based on the cumulative method, there are no potential recoverable PIS and COFINS taxes in the lease installments payable.





### 17 Debentures


	Parent Company		Consolidated	
	03/31/21	12/31/20	03/31/21	12/31/20
Non-convertible debentures Interests Transaction cost	3,531,667 30,375 (8,421)	3,531,667 14,691 (9,149)	4,137,715 30,113 (9,313)	4,132,758 14,429 (10,179)
	3,553,621	3,537,209	4,158,515	4,137,008
Current	460,842	145,133	466,458	145,720
Non-current	3,092,779	3,392,076	3,692,056	3,991,288

Changes in debentures are as follows:

	Parent Company	Consolidated
Balance as at December 31, 2019	<u>2,715,986</u>	<u>2,715,986</u>
Fund raising Acquisition of subsidiaries Interest incurred Interest paid Principal amortization Transaction cost	965,000 100,959 (104,719) (133,333) (6,684)	965,000 601,571 123,061 (91,391) (170,535) (6,684)
Balance as at December 31, 2020	3,537,209	4,137,008
Interest incurred Interest paid Transaction cost	24,761 (8,106) (243)	29,856 (8,106) (243)
Balance as at March 31, 2021	<u>3,553,621</u>	4,158,515

Debentures classified in non-current liability have the following amortization:

	Parent Company	Consolidated
Until April 2022	724,960	924,719
2023	719,974	919,734
2024	786,563	986,322
2025 to 2027	861,282	861,281
	<u>3,092,779</u>	3,692,056





### **Debentures - parent company**

The issuances of non-convertible debentures into shares, unsecured, were approved by the Company's Board of Directors, through public offering of distribution with restricted efforts, under the terms of CVM Instruction No. 476, of January 16, 2009, as amended, set forth below:

Issuance	Series	Approval date	Quantit y	Total amount obtained	Term (counted from the issuance)	Compensation 108.00% of DI	Principal amortization 3 installments - 1° 08/25/2020.
$8^{\text{th}}$	Single	08/08/2017	40,000	400,000	5 years	Semi-annual payment	2 <sup>a</sup> 08/25/2021 and 3 <sup>a</sup> 08/25/2022 2 installments - 1° 03/26/2022
9 <sup>th</sup>	Single	02/05/2018	60,000	600,000	5 years	108.60% of DI	and 2 <sup>a</sup> 03/26/2023 2 installments - 1° 12/10/2022
$10^{\rm th}$	1 <sup>st</sup>	11/19/2018	10,000	100,000	up to 5 years	107.40% of DI	and 2 <sup>a</sup> 12/10/2023
$10^{\rm th}$	$2^{\rm nd}$	11/19/2018	30,000	300,000	6 years	110.50% of DI	12/10/2024
$10^{\mathrm{th}}$	$3^{\mathrm{rd}}$	11/19/2018	40,000	400,000	up to 8 years	112.50% of DI	2 installments - 1° 12/10//2025 and 2ª 12/10/2026
11 <sup>th</sup>	Single	05/17/2019	40,000	400,000	up to 7 years	108.50% of DI	2 installments - 1° 06/10/2025 and 2ª 06/10/2026
12 <sup>th</sup>	Single	11/22/2019	500,000	500,000	5 years	100% of DI + 1.2% p.a.	2 installments - 1° 11/25/2023 and 2ª 11/25/2024
13 <sup>th</sup>	Single	08/04/2020	365,000	365,000	3 years	100% of DI + 1.95% p.a.	3 installments - 1° 04/13/2022. 2° 10/13/2022 and 3° 04/13/2023
14 <sup>th</sup>	1 <sup>st</sup>	10/20/2020	475,650	475,650,000	5 years	100% of DI + 2.10% p.a.	2 installments - 1° 10/20/2024 and 2° 10/20/2025
14	1	10/20/2020	473,030	4/3,030,000	3 years	2.10% p.a. 100% of DI +	2 installments - 1° 10/20/2026
$14^{th}$	$2^{nd}$	10/20/2020	124,350	124,350,000	7 years	2.40% p.a.	and 2ª 10/20/2027

The net funds obtained by the Company with the issuance of Debentures were fully used to extend its indebtedness profile and reinforce its working capital to meet its daily business management.

The operations of debentures contracted by the Company require compliance with restrictive financial covenants, under penalty of early maturity of the related debts. The noncompliance with the obligations or restrictions for two consecutive quarters may cause the early maturity of the related debts and default in relation to other contractual obligations (*cross-default*), depending on each loan and financing agreement. The compliance rates are the same as those mentioned in Note 15.


#### Debentures subsidiary Ímpar Serviços Hospitalares S.A.

On October 30, 2019, the Board of Directors of the subsidiary Impar Serviços Hospitalares S.A. approved the issuance of 600,000 (six hundred thousand) simple debentures, nonconvertible into shares, unsecured, with additional real guarantee, in single series, with unit nominal value of R\$ 1,000.00 (one thousand reais), totaling, on the issuance date, that is December 10, 2019, the amount of R\$ 600,000 for public distribution, with restricted distribution efforts, as shown below:

Issuance	Series	Approval date	Quantity	Amount obtained	Term (counted from the issuance)	Compensation	Principal amortization
1 <sup>st</sup>	Single	10/30/2019	600	R\$ 600,000	5 Years	CDI + 1.40%	06/10/2022 - 12/12/2022 06/12/2023 - 12/11/2023 06/10/2024 - 12/10/2024

### Financial and non-financial covenants - Early maturities

The fiduciary agent shall declare the early maturity of obligations derived from the debentures and require the immediate payment, by Ímpar, of the debt balance of the unit nominal value of debentures plus compensation of interest for the period, in case Ímpar fails to comply with certain contractual clauses, considered as events of default.





The debentures issued by the subsidiary İmpar Serviços Hospitalares S.A. contain contractual clauses establishing maximum levels of indebtedness and leverage, based on their annual financial statements. The noncompliance with these contractual clauses may cause the early maturity of the debt balance of the debentures plus compensation of interest for the period.

### 18 Taxes in installments


		Parent Company		Consolid	ated
	End of Amortization	03/31/21	<u>12/31/20</u>	03/31/21	12/31/20
ISS Installment	2029	4,415	5,511	5,914	3,661
Refis (Tax recovery program) Municipal - Ímpar	2025	-	-	17,285	18,987
Refis (Tax recovery program) IV - Federal - Ímpar	2024	-	-	39,404	48,825
Refis (Tax recovery program) IV - Lab. Gaspar	2024	-	-	1,260	1,459
Federal Taxes Installment	2021	2,046	1,468	16,074	6,701
Installment rate of solid waste - SZD	2022	-	-	728	1,005
Installment PERT - Santa Luzia	2021	-	-	429	483
Federal Taxes Installment -Valeclin	2028	-	-	2,193	2,346
Others	2021	193	244	<u>1,483</u>	<u>1,609</u>
		<u>6,654</u>	<u>7,223</u>	<u>84,770</u>	<u>85,076</u>
Current		<u>2,494</u>	<u>2,627</u>	<u>27,996</u>	23,150
Non-current		<u>4,160</u>	<u>4,596</u>	<u>56,774</u>	61,926

## 19 Accounts payable from acquisition of subsidiaries and options with noncontrolling shareholders

Accounts payable from acquisition of subsidiaries refer to amounts due to former owners upon acquisition of shares or quotas representing the capital stock of the acquired entities. The debts are updated in accordance with contractual clauses:

	<u>-</u>		Parent Company			Consolidated	
	<u>Update</u>	<b>Maturity</b>	03/31/21	12/31/20	03/31/21	12/31/20	
Not guaranteed by financial investments Guaranteed by financial	IPCA-IGPM- Selic	06/2025	396,678	419,203	440,380	431,031	
investments	(a)	(a)	38,547	38,386	38,666	38,505	
Contingent consideration			<u>72,273</u>	<u>67,267</u>	<u>72,273</u>	67,267	
			507,498	<u>524,856</u>	<u>551,319</u>	<u>536,803</u>	
Current			163,841	116,638	173,020	121,408	
Non-current			<u>343,657</u>	<u>408,218</u>	<u>378,299</u>	<u>415,395</u>	

<sup>(</sup>a) Both financial investment and liability are remeasured at the rate of 90% of CDI as at March 31, 2021 and December 31, 2020. The maturity term is of up to 6 years from the acquisition date, or until the conclusion of the discussion about the contingency. The financial investments are recorded and disclosed under separate caption in non-current asset.





The transaction of Accounts payable from acquisition of subsidiaries in the consolidated is as follows:

	Not guaranteed by financial investments	Not guaranteed by financial investments - international	Guaranteed by financial investments	Contingent consideration	Total
Balance as at December 31, 2019	<u>117,452</u>	<u>204,496</u>	<u>41,483</u>	<u>40,300</u>	<u>403,731</u>
Acquisitions Interest incurred and	164,343	-	1,569	15,300	181,212
exchange rate variation Payments	4,052 (57,345)	60,729 (62,696)	877 (5,424)	12,667 (1,000)	78,325 (126,465)
Balance as at December 31, 2020	<u>228,502</u>	<u>202,529</u>	<u>38,505</u>	<u>67,267</u>	536,803
Acquisitions Interest incurred and	<u>36,826</u>	Ē	Ē	≣	<u>36,826</u>
exchange rate variation Remeasurement of fair	<u>365</u>	<u>19,767</u>	<u>161</u>	<u>5,006</u>	<u>25,299</u>
value Payments	(5,663) (41,946)	<u>=</u> <u>=</u>	= =	= =	(5,663) (41,946)
Balance as at March 31, 2021	<u>218,084</u>	<u>222,296</u>	<u>38,666</u>	<u>72,273</u>	<u>551,319</u>

The installments classified in non-current liability mature as follows:


Year of maturity	Consolidated		
2022	262,790		
2023	84,147		
2024	8,900		
From 2025	<u>22,462</u>		
Total	<u>378,299</u>		

### Put and call option granted to non-controlling shareholders

As part of the agreement to acquire equity interest, a put option ("put") was issued by the Company in favor of non-controlling shareholders and a call option was issued by the sellers in favor of the Company, which may result in the acquisition by the Company of the remaining shares of non-controlling shareholders, summarized as follows:

Put option granted to non-controlling shareholders:

	Put options:
Balance as at December 31, 2019	-
Laboratório Nobel S/A	16,552
Instituto de Hematologia de São José do Rio Preto Ltda.	5,694
DB Genética Serviços Laboratoriais Ltda.	5,691
CPCLIN - Centro de Pesquisa Clinicas Ltda.	1,022
Laboratório Bioclínico MS Ltda.	10,500
Balance as at December 31, 2020	<u>39,459</u>
Laboratório Nobel S/A	11,442
Instituto de Hematologia de São José do Rio Preto Ltda.	4,995
DB Genética Serviços Laboratoriais Ltda.	6,069
CPCLIN - Centro de Pesquisa Clinicas Ltda.	780
Laboratório Bioclínico MS Ltda.	<u>17,421</u>
Balance as at March 31, 2021	40,707
Current	34,638
Non-current	<u>6,069</u>





Call option granted to non-controlling shareholders:

	Call option
Balance as at December 31, 2019:	-
Laboratório Nobel S/A Instituto de Hematologia de São José do Rio Preto Ltda. DB Genética Serviços Laboratoriais Ltda. CPCLIN - Centro de Pesquisa Clinicas Ltda. Laboratório Bioclínico MS Ltda.	1,000 1,270 1,322 1,454 2,423
Balance as at December 31, 2020:	<u>7,469</u>
Laboratório Nobel S/A Instituto de Hematologia de São José do Rio Preto Ltda. DB Genética Serviços Laboratoriais Ltda. CPCLIN - Centro de Pesquisa Clinicas Ltda. Laboratório Bioclínico MS Ltda.	1,133 1,515 1,175 1,152 448
Balance as at March 31, 2021:	<u>5,423</u>
Current Non-current	4,248 1,175

### 20 Provisions for labor, civil and tax security claims

		Parent Company			Consolidated			
	03/31	/21	12/31/20		03/31/21		12/31/20	
	Provision	Judicial deposit	Provision	Judicial deposit	Provision	Judicial deposit	Provision	Judicial deposit
Labor and civil Tax and social security claims	61,663 87,903	17,048 <u>64,163</u>	53,143 70,798	16,918 <u>64,163</u>	101,974 111,725	32,277 69,480	107,356 <u>94,062</u>	30,885 69,418
	149,566	81,211	123,941	81,081	213,699	101,757	201,418	100,303

#### Provisions for labor and civil risks

As at March 31, 2021, DASA Group was party to R\$ 1,648 labor lawsuits (R\$ 1,456 as at December 31, 2020) and to R\$ 1,833 civil lawsuits at administrative and judicial levels (R\$ 1,761 as at December 31, 2020). The provisions of R\$ 61,663 (R\$ 53,143 as at December 31, 2020) in the parent company and R\$ 101,974 (R\$ 107,356 as at December 31, 2020) in the consolidated, are based on the historical percentage of losses in proceedings with probable and possible risk for labor lawsuits and probable risk for civil lawsuits.

In relation to labor lawsuits, we point out the Public Civil Action in progress at the Labor Court of Rio de Janeiro which summoned the Company and Laboratórios Physicians Dr. Sérgio Franco Ltda., company incorporated by the Company on July 01, 2014, which, in general terms, challenges the lawfulness of the hiring of medical companies specialized in the area of supporting diagnostic imaging exams, requiring the hiring of physicians, linked to these medical companies, under the CLT regime, and indemnity for collective moral damage in the amount of approximately R\$ 20,000 on September 10, 2012. On June 26, 2014, the Company disclosed new Material Fact informing that decision was given at lower courts fully favorable to the Company. On February 24, 2015, the Regional Labor Court provided partially the Appeal filed by the Prosecutors Office and convicted the Company to register the consenting intervening physicians - which represents approximately 22 professionals - as well as the reduction of the collective moral damage to R\$ 500. The decision of the TRT - 1st Region defined intervening physicians as follows: "(are those) who exercise coordination of executor physicians in the same specialty". The Company, and the Prosecutors Office filed motions for clarification in relation to the decision. The motions of the Prosecutors Office were rejected and the motions of the Company were accepted, however, without the effect of changing the decision. The bill of review filed by the Prosecutors Office was denied. On January 27, 2016, the MPT filed interlocutory appeal. On May 03, 2016 we filed (i) written reply against the interlocutory appeal, (ii) counter arguments of bill of review and (iii) adhesive bill of review. The opinion of legal advisors and Management is that the loss is probable for moral damage of approximately 22 professionals in the updated amount of R\$ 1,321, and remote for collective moral damage in the amount of R\$ 19,500.

(In thousands of reais, unless otherwise stated)



#### Provisions for tax and social security claims


The provisions for tax and social security claims in the amount of R\$ 71,094 (R\$ 70,798 as at December 31, 2020) in the parent company and R\$ 94,917 (R\$ 94,062 as at December 31, 2020) in the consolidated, correspond to (i) questionings of increase of tax rates, (ii) tax basis and (iii) unconstitutionality of the collection. The Company and its subsidiaries also had as at March 31, 2021 the consolidated amount of R\$ 764,757 (R\$ 787,649 as at December 31, 2020) related to lawsuits classified by its legal advisors as possible loss, for which no provision had been recognized, in accordance with the accounting rule applicable in the circumstance, where R\$ 188,753 refers to ISSQN lawsuits which basically discusses the place of provision of services of clinical analyses, R\$ 96,723 refers to the collection of PIS/COFINS on billing and import, IRPJ and CSLL credits in the amount of R\$ 92,184, IRPJ and CSLL in the amount of R\$ 227,299 originated from deduction of goodwill on incorporation.

On March 7, 2016, Management became aware of an administrative lawsuit of the Brazilian Federal Revenue Service (RFB) regarding 2 assessment notices requiring the collection of PIS and COFINS in total amount of R\$ 55,629. On July 15, 2016, the Company filed Declaratory action No. 0004053-41.2016.4.03.6144, in progress at the 1st Federal Court of the Judiciary Subsection of Barueri-SP, aiming to assure in advance the full amount of tax debts object of the Tax Foreclosure through the offer of insurance policy collateral issued on July 13, 2016, strictly in conformity with PGFN Ordinance No. 164/2014, as well as articles 151, item V, and 206 of CTN. The Tax Foreclosure No. 0006303-47.2016.403.6144 was filed on August 10, 2016 for collection of CDAs 80 6 16 053101-28 and 80 7 16 021700-63, whose objects are PIS and COFINS debts for the year 2011 derived from the Federal Administrative Process No. 16004.720192/2015-69 filed by the Brazilian Federal Revenue Service. On May 12, 2017 judgment was given confirming the decision of urgency injunction and upheld the declaratory action to determine the record that the tax credits charged by the tax foreclosure are guaranteed by legitimate insurance collateral. The Company was summoned to respond to the terms of the Tax Foreclosure No. 0006303-47.2016.403.6144, reason for submitting a statement in the records of the Declaratory action with Request for Provisional Injunction No. 0004053-41.2016.4.03.6144 informing the existence of the present tax foreclosure and requiring the transfer of the collateral. After complying with the requirements provided for in articles 16, items I and II, of Law No. 6,830/80, 184, caput and paragraph 1, of CPC, and 62, item I, of Law No. 5,010/66, on September 27, 2017, the Company filed Embargos to the Tax Foreclosure, being registered in the electronic systems of the 1st Federal Court of the Judiciary Subsection of Barueri-SP under No. 0003688-50.2017.403.6144. On April 12, 2018 it was published decision on the Embargos to the Tax Foreclosure, determining the indication of evidence to be produced, which was met by the Company on time, on April 20, 2018. In November 2018, it was published decision requesting that the Company indicate items and the technical assistant within 15 days, which were presented on timely basis. Finally, the Company's outside legal advisors believe that the chance of loss on the merits of such lawsuit is possible, for which no provision had been recognized.

The Company filed Declaratory action No. 1005652-68.2018.4.01.3400 against the Federal Government seeking the acceptance of urgency provisional injunction in order to assure to the Company the deduction, in the IRPJ and CSLL tax bases, of the amortization of goodwill from incorporation, suspending the mandatory controverted amount. On April 16, 2018, decision was given accepting the urgency provisional injunction seeking to suspend the mandatory controverted amount provided that the insurance collateral is accepted by the Federal Government. On May 4, 2018 the Federal Government filed motions for clarification challenging the acceptance of the insurance policy collateral as a way to suspend the demand for credit. In view of the impossibility to continue with the insurance collateral, the Company made an escrow deposit in the amount of R\$ 33,350 until October 2018, which already includes fine and arrears interest, which corresponds to the amounts of IRPJ and CSLL calculated on the deduction in the tax base of such taxes. The Company's outside legal advisors believe that the chance of loss on such lawsuit is possible, for which no provision had been recognized. On May 28, 2020, the Brazilian Federal Revenue Service concluded the procedure of inspection of the deductibility of the goodwill, stating the sufficiency of the court deposits and disallowing, concurrently, IRPJ tax loss and CSLL tax loss carryforwards in proportion to the goodwill used for tax purposes. The Company believes that there are legal grounds for the use of the goodwill and will overrule the assessment notices on administrative basis. Concurrently, the lawsuit will have regular course, and the Company may use the deductibility of these amounts after the final and unappealable decision on the lawsuit in case the final decision is favorable to the Company. The Company's outside legal advisors believe that the risk of loss on the litigation is possible, for which no provision had been recognized since there is no related tax exposure.

#### Transaction of provisions for contingencies as at March 31, 2021

			Pare	ent Company				
		Movement in the period						
	12/31/20	Addition from business combination	Addition to provision	Use	Update (reversal)	03/31/21		
Labor and civil Tax and social security claims	53,143 70,798	<u>16,809</u>	12,824 	(4,304) (2,521)	489	61,663 87,903		
	123,941	<u>16,809</u>	<u>15,152</u>	(6,825)	489	149,566		





	Movement in the period						
	12/31/20	Addition to provision	Addition from acquisition of subsidiaries	Use	Update (reversal)	03/31/21	
Labor and civil Tax and social security claims	107,356 94,062	1,058 2,349	<u>21,867</u>	(6,440) (7,580)	_1,027	101,974 111,725	
	201,418	<u>3,407</u>	<u>21,867</u>	_(14,020)	_1,027	213,699	
Transaction of provisions for conti	ingencies as at	December 31	, 2020				
			Pare	nt Company			
		Movement in the year					
	12	2/31/19	Addition to provision	Use	Update (reversal)	12/31/20	
Labor and civil Tax and social security claims		44,566 62,592	24,212 10,592	(15,630) (5,317)	(5) 2,931	53,143 70,798	
	<u>1</u>	07,158	<u>34,804</u>	(20,947)	<u>2,926</u>	<u>123,941</u>	

Consolidated

Consolidated


		Movement in the year					
	12/31/19	Addition to provision	Addition from acquisition of subsidiaries	Use	Update (reversal)	12/31/20	
Labor and civil Tax and social security claims	50,865 89,715	25,676 16,559	52,171 2,047	(17,022) (17,355)	(4,334) 3,096	107,356 <u>94,062</u>	
	<u>140,580</u>	<u>42,235</u>	<u>54,218</u>	(34,377)	(1,238)	<u>201,418</u>	

## 21 Share-based payment

The Company offers to the executives share-based compensation plan. Currently there are two plans in effect, "Plan 2016" for the period from 2016 to 2019 duly approved at the Extraordinary Shareholders' Meeting on April 25, 2016 and subsequently amended at the Extraordinary Shareholders' Meeting held on May 25, 2017("Plan 2016"). The Company at Extraordinary Shareholders' Meeting held on December 5, 2018 approved the share-based payment/compensation plan through the granting of premiums ("Plan 2018"), and granted the opportunity to participants of the "Plan 2016" to opt, at their sole discretion, to substitute the premiums held by them under the "Plan 2016" for options under this "Plan 2018"; and "Plan 2020" for the period from 2020 to 2023 approved at the Extraordinary Shareholders' Meeting on November 30, 2020.

These plans have the following characteristics/purposes:

- (a) Has the purpose to establish our share-based compensation plan, allowing the Company to align its interests with those of its shareholders and beneficiaries, attract and retain talents, increase the generation of sustainable results and reinforce the long-term orientation in the decision-making of the Company's executives and employees.
- (b) The Beneficiaries shall be chosen and elected by the Board of Directors, at its sole discretion.






- (c) The Plans will be managed by the Board of Directors, who may establish a committee to assist them in this regard and, to the extent permitted by law, by the Company bylaws, will have ample powers to take all necessary and appropriate actions to manage the plans.
- (d) For "Plan 2018" the maximum number of Shares that can be actually used as base for exercise of premiums granted cannot exceed 19,902,320 Shares, representing, on the date of creation of Plan 2018, approximately 6% of the capital stock of the Company. For "Plan 2020" the Board of Directors may approve the partial or total settlement of the Options exercised in cash; the Options to be granted under "Plan 2020" cannot exceed 28,848,825 (twenty-eight million, eight hundred forty-eight thousand, eight hundred twenty-five) Options, representing, on the date of approval of "Plan 2020", approximately 6% (six percent) of the capital stock of the Company.
- (e) The exercise price is defined (based on the fair value of shares on the granting date determined as provided for in item (f) below) for each granting and is monetarily adjusted by an inflation index and the grace period (service condition) is usually of 4 years. The premiums should be fully exercised at the end of the grace period.
- (f) The premiums can be exercised in shares or directly in cash, after the expiry of the *vesting* period established in each grant agreement (average of four years per grant), at the discretion of the executive holding the options. The Company will open annual repurchase plans, whose total amount is limited to R\$ 70 million, being the executive responsible for choosing the put option of shares and/or the exercise of the options in cash. In order to determine the amounts of cash settlement, the agreement establishes that the company should determine the fair value of its shares using market multiples of peer companies, since the Company does not have significant volume of shares traded, and its own data, such as EBITDA and debt. The agreement also establishes that, if the Company has significant volume of shares traded, the Company should use as criterion of valuation the value of the share traded on the stock exchange (average trading floor operations for the last thirty days).
- (g) The fair value was measured under the Black-Scholes method. The expected volatility was based on the evaluation of the historical volatility of the price of shares of peer companies, particularly over the historical period proportional to the expected term.

In 2020, there was a change in "Plan 2018" according to which the grace period of non-exercised premiums was extended for more three years.

(h)	Grants Plan 2018			Grants Plan 2020	
	1 <sup>st</sup>	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	1 <sup>st</sup>
Fair value	20.55	9.93	7.32	12.61	14.04
Share price	32.36	32.36	32.36	36.32	40.37
Exercise price	12.30	24.88	29.01	30.40	40.30
Expected volatility	46.96	46.96	46.96	46.96	46.96
Useful life	4 years	4 years	4 years	4 years	4 years
Risk free rate	5.25%	5.25%	4.5%	4.5%	4.5%





Under Plan 2018, the following grants have been approved:

Approval exercise	Approval	Quantity
2016	Board of Directors	5,812,241 Options
2017	Board of Directors	6,572,842 Options
2018	Board of Directors	4,663,274 Options
2019	Board of Directors	5,215,000 Options

Under Plan 2020, the following grants have been approved:

Approval exerciseApprovalQuantity2021Board of Directors7,181,250 Options

The provision for share-based payment is the following:

		Taxes and		
	Plan	charges	Total	
Balance as at December 31, 2019	150,287	61,317	211,604	
Provision Reversal of provision Payments	29,447 (78,122) (69,803)	7,361 (46,549) (14,176)	36,808 (124,671) (83,979)	
Balance as at December 31, 2020	<u>31,809</u>	<u>7,953</u>	<u>39,762</u>	
Provision for liability (Note 25) Payments	113,352 (1,168)	37,784 (389)	151,136 (1,557)	
Balance as at March 31, 2021	<u>143,993</u>	<u>45,348</u>	<u>189,341</u>	
Current Non-current	116,723 27,270	38,908 6,440	155,631 33,710	

## 22 Equity

### Share capital

The capital stock of the Company as at March 31, 2021 is R\$ 12,326,706 (R\$ 12,326,706 as at December 31, 2020), represented by 480,813,758 common shares, all registered, book entry and without nominal value.

The limit of increase of the authorized capital stock, irrespective of statutory reform, upon issuance of new shares as long as the capital does not exceed 1,000,000,000 (one billion) common shares.

The Board of Directors' meeting held on January 23, 2020 approved the capital increase, with issuance of 165,759,713 new common shares, in total amount of R\$ 10,000,283.

(In thousands of reais, unless otherwise stated)



### **Equity valuation adjustment**

As result of the transaction carried out with Impar, as it is a transaction between entity under common control and no goodwill should be recognized as increase of shareholder's equity, after the acquisition, aiming to adapt all the corporate procedures performed in conformity with the Brazilian Corporate Law to the accounting aspects, the amount of amount R\$ 9,243,943 was recorded as equity valuation adjustment, reducing the shareholder's equity and equalizing the effects at cost value.

This caption also included the effects of translation of the presentation currency of the subsidiaries abroad and of hyperinflation in the Argentine subsidiary.

### **Treasury shares**

In the first quarter of 2021 there was no transaction with treasury shares, as shown below:

Descriptions	Number of shares	Average price per share in Reais	Shares in Reais
Balance as at December 31, 2019	109,199	22.20	2,424
Acquisitions	1	10.36	-
Disposals (a)	(17,534)	<u>65.00</u>	(1,140)
Balances as at March 31, 2021 and December 31, 2020	<u>91,666</u>	<u>14.01</u>	<u>1,284</u>


<sup>(</sup>a) Disposal of treasury shares for the purpose of exercising options to purchase equity interest in Laboratório Santa Luiza, which is quoted in the market at the time of acquisition.

### Loss per share (basic and diluted)

The base loss per share is calculated by dividing the loss attributable to Company shareholders by the weighted average of the number of common shares issued in the period, excluding common shares purchased by the Company and kept as treasury shares.

	01/01/21 to 03/31/21	01/01/20 to 03/31/20
Loss attributable to the Company's controlling shareholders	(12,372)	(78,135)
Weighted average of the quantity of common shares issued (in thousands)	480,814	480,814
Weighted average of treasury shares (in thousands)	(92)	(109)
Weighted average of the number of outstanding common shares (in thousands)	480,722	480,705
Basic loss per share - (in R\$)	(0.02574)	(0.16254)

Diluted loss per share is calculated by adjusting the weighted average of the number of common shares outstanding considering the conversion of all potential common shares that would cause such dilution. The Company issued a single class of potential common shares that would cause dilution, which are the stock option plan options.





	01/01/21 to 03/31/21	01/01/20 to 03/31/20
Loss attributable to the Company's controlling shareholders	(12,372)	(78,135)
Weighted average of the number of outstanding common shares (in thousands)) Adjustment for stock options (in thousands) (a) Quantity weighted average of common shares for diluted loss per share (in thousands)	480,722 29,445 510,167	480,705 19,902 500,607
Diluted loss per share - (in R\$)	(0.02425)	(0.15608)

<sup>(</sup>a) These result in the issuance of common shares for less than the average market price of common shares during the period, therefore they act as dilutors. Details are described in Note 21).

### Dividends and interest on own capital

According to the Company's bylaws, the net profit for the year is directed as follows: (i) 5% for the establishment of the legal reserve, until it reaches 20% of the subscribed stock capital; and (ii) at least 25% of the remaining balance adjusted pursuant to art. 202 of Law 6,404/76, for the payment of mandatory dividends.

On December 30, 2020, the Board of Directors approved *ad referendum* of the Shareholders' Meeting which decided on interest on equity in the total gross amount of R\$ 137,197 (R\$ 0.28539720219 per share) on the financial statements of the fiscal year closed as at December 31, 2020.

The form of payment of interest on equity is described below:

Description	Parent Com	Parent Company		nted
Approval date Payment date	12/31/20 04/30/21	12/23/19 02/20/20	12/31/20 04/30/21	12/23/19 02/20/20
Interest on distributed equity (a) (-) Tax withheld at source	137,027 (20,580)	177,457 (26,425)	263,701 (39,555)	194,264 (29,140)
Interest on net equity	<u>116,627</u>	<u>151,032</u>	<u>224,146</u>	<u>165,124</u>
(+) Withholding income tax - residents abroad (-) Payment of interest on equity	<u>7,189</u>	<u> </u>	<u>7,189</u> (19,970)	<u>=</u>
	<u>123,816</u>	<u>151,032</u>	211,365	<u>165,124</u>

<sup>(</sup>a) Minimum mandatory dividends are already included in the Interest on distributed equity.



### 23 Net revenue from services

The conciliation between gross revenue, for fiscal purposes, and the Net operating revenue as presented in the statement of results for the period is shown below:

	Parent Co	ompany	Consolidated	
	03/31/21	03/31/20	03/31/21	03/31/20
Revenue by sector:				
National private	1,260,526	873,268	1,553,585	1,025,294
Foreign private	-	-	90,799	46,793
Governmental	-	-	73,948	51,358
Hospital			847,172	471,401
	<u>1,260,526</u>	873,268	<u>2,565,504</u>	<u>1,594,846</u>
Deductions:				
Taxes on revenue	(75,583)	(52,836)	(148,927)	(92,734)
Disallowances variable consideration	1,229	(17,200)	(34,080)	(37,004)
Commercial discounts	(5,893)	(7,711)	(5,983)	(8,240)
Net operating revenue	<u>1,180,279</u>	795,521	2,376,514	1,456,868

DASA Group has a certain degree of concentration in our customer portfolios. As at March 31, 2021 and 2020, the concentration in the five main customers was as follows:

	03/31/21	03/31/20
CUSTOMER A	15.4%	9.1%
CUSTOMER B	11.4%	7.9%
CUSTOMER C	9.2%	5.9%
CUSTOMER D	4.0%	3.7%
CUSTOMER E	3.3%	1.4%

## 24 Cost of services rendered

	Parent Con	npany	Consolid	ated
	03/31/21	03/31/20	03/31/21	03/31/20
Expenses with personnel	(196,203)	(160,691)	(411,561)	(327,410)
Cost with materials	(238,545)	(130,434)	(518,628)	(265,480)
Cost with services and utilities	(239,456)	(168,901)	(552,761)	(332,022)
Costs with depreciation and amortization	(84,753)	(82,637)	(152,047)	(114,185)
General costs	(12,555)	(12,878)	(24,210)	(24,655)
	(771,512)	(555,541)	(1,659,207)	(1,063,752)



## 25 Administrative and general expenses

	Parent Company		Consolid	ated
	03/31/21	03/31/20	03/31/21	03/31/20
Expenses with personnel	(91,341)	(87,583)	(202,034)	(139,361)
Provision for interest in profits, results, and bonuses	(26,053)	(19,242)	(35,151)	(26,334)
Share-based payments (Note 21)	(151,136)	` · · · · -	(149,396)	` · · · · · · · ·
Services and utilities	(79,296)	(51,124)	(143,311)	(85,134)
Advertising and publicity	(13,851)	(9,689)	(16,887)	(13,015)
Expenses with transportation	(27,815)	(16,607)	(34,619)	(19,186)
Depreciations and amortizations	(45,437)	(36,339)	(59,004)	(50,363)
Taxes and rates	(1,721)	(730)	(6,215)	(3,625)
(Provisions)/Reversal of miscellaneous provisions	(9,113)	(7,652)	3,412	(11,833)
Others	(12,599)	(17,715)	(31,789)	(29,830)
	(458 362)	(246 681)	(674 994)	(378 681)


## 26 Others operating income (expenses)

	Parent Company Consolidated		lated	
	03/31/21	03/31/20	03/31/21	03/31/20
Other income				
Result of property, plant and equipment sale	32	69	264	94
Revenues of real estate lease	87	90	3,362	138
Recovery of third parties' credits (a)	-	-	3,458	1,995
Others miscellaneous income	<u>1,115</u>	592	4,257	_1,287
	<u>1,234</u>	<u>751</u>	11,341	<u>3,514</u>
Other expenses				
Inventories write-off	(334)	(1,155)	(501)	(1,286)
Others miscellaneous services	<del></del>	_(165)	<u>(726)</u>	(353)
	<u>(334)</u>	(1,320)	(1,227)	(1,639)

<sup>(</sup>a) Refers to revenue from administrative proceeding services provided by Maipú to local companies in Argentina.

### 27 Net finance costs

	Parent Com	pany	Consolid	ated
	03/31/21	03/31/20	03/31/21	03/31/20
Financial expenses				
Interest	(36,104)	(36,450)	(48,470)	(44,902)
Passive exchange and monetary variations	(54,758)	(71,023)	(73,135)	(137,612)
Adjustments to present value - AP	(246)	(1,512)	(246)	(1,512)
Interest on lease of right of use	(20,866)	(21,753)	(44,448)	(22,111)
Others	(8,827)	(4,873)	(13,752)	_(13,659)
	(120,801)	(135,611)	(180,051)	(219,796)
Financial income				
Interest	4,908	6,613	9,856	8,575
Derivative financial instruments	-	-	15,660	64,235
Active exchange and monetary variations	43,290	1,144	29,496	6,835
Others	100	17	1,079	345
	48,298	7,774	56,091	79,990
	<u>(72,503)</u>	(127,837)	(123,960)	(139,806)





### 28 Income tax and social contribution

DASA Group monthly provisions installments for income tax and social contribution over net profit, on an accrual basis.

Conciliation of expenses calculated by applying the combined fiscal aliquots and expenses with income tax and social contribution debited on the result is demonstrated as follows:

	Parent Co	Parent Company Conso		olidated	
	03/31/21	03/31/20	03/31/21	03/31/20	
Loss before income tax and social contribution	(81,157)	(132,501)	(71,533)	(123,496)	
Combined tax rate	34%	34%	34%	34%	
Income tax and social contribution: At combined tax rate	27,593	45,050	24,321	41,989	
Effect of tax rates in foreign jurisdictions (30%)	-	-	-	-	
Permanent exclusions (additions) Result of equity accounting Non-deductible expenses (i)	13,614 (2,310)	886 (679)	(1,507)	(4,191)	
Other adjustments Assumed profit (ii) Recognition of tax loss and negative basis (iii) Others	28,703 1,184 68,784	9,109 54,366	(319) 28,703 9,427 60,625	(657) - 8,867 46,008	
Current income tax and social contribution Deferred taxes	68,784	54,366	(19,294) 79,919	(8,671) 54,679	
Total	68,784	54,366	60,625	46,008	
Effective rate (iv)	-42%	-41%	-41%	-37%	


<sup>(</sup>i) These are expenditures that cannot be deducted for tax purposes, under the terms of applicable tax legislation, such as: expenses with fines, donations, gifts and certain provisions.

The combined tax rate used in the March 31, 2021 and 2020 assessments is 34%, due by legal persons in Brazil over taxable profits, as provided for in the Country's tax legislation.

<sup>(</sup>ii) The Brazilian tax legislation provides for an alternative method of taxation for companies that earned gross revenues of up to R\$ 78 million in their previous fiscal year, denominated *presumed profit*. Certain subsidiaries of the Company have adopted this alternative form of taxation, according to which the IRPJ and CSLL were calculated on an 8% basis over the operation's revenues, instead of calculating them based on the actual real profit of these subsidiaries. The presumed profit adjustment represents the difference between taxation under this alternative method and what would have been due based on the official rate applied to the actual profit of these subsidiaries.

<sup>(</sup>iii) It refers to deferred income tax and social contribution on a share-based plan from previous year.

<sup>(</sup>iv) Reconciliation of the effective tax rate is based on their domestic rates, including a reconciliation item relating to tax rates applied by companies in another jurisdiction. Reconciliation at the effective tax rate is based on an applicable tax rate that provides the most significant information to users.






## Deferred taxes on tax losses and temporary provisions

Deferred income tax and social contribution are recorded to reflect future fiscal effects attributable to temporary differences between the fiscal base of assets and liabilities and their respective book value.

According to CPC 32 / IAS 12, DASA Group, based on expected generation of future taxable profits, in a technical study approved by our Management, recognizes tax credits and debits on deductible temporary differences and on fiscal losses and accumulated negative bases on social contributions, which have no deadline for enforcement and which compensation is limited to 30% of annual taxable profits. The book value of the asset and of the deferred tax liabilities is reviewed quarterly, and the projections are reviewed annually.

The composition of balances relating to deferred income tax and social contributions, assets and liabilities, is shown below:

	Balance Sheet Parent Company		Income Statement Parent Company	
	03/31/21	12/31/20	03/31/21	03/31/20
Tax loss and negative basis	584,523	544,147	40,376	67,481
Expected credit losses ("impairment") of trade receivables	34,120	35,720	(1,600)	2,317
Expected disallowances variable consideration	17,576	15,308	2,268	1,192
Provision Specialized medical services	(2,059)	(765)	(1,294)	(4,751)
Miscellaneous provisions	104,170	75,624	28,547	4,744
Provisions for obsolescence	2,777	2,687	90	(393)
Adjustments to present value - APV	5,393	5,589	(195)	242
Provision for contingencies	34,650	32,326	2,323	3,160
Review of the useful life of property, plant and equipment	25,904	25,983	(79)	337
Others	837	808	28	34
Deferred charges on reverse merger of subsidiary	303,227	301,202	2,025	(16,376)
Amortization of goodwill	(660,166)	(655,545)	(4,621)	(4,378)
Intangible Assets identified in interest acquisitions	(58,490)	(59,345)	855	855
Others	(3,878)	(3,940)	62	(98)
Deferred income tax and social contribution	388,584	319,799	68,785	54,366
Asset variation that does not affect the result				
Surplus value effect in acquisition of subsidiaries	<u>(7,698)</u>			
	<u>380,584</u>			
Reconciliation of Deferred Tax Assets (Liabilities)				
Opening Balance - December 31, 2020	319,799			
Tax revenue recognized in the income statement	68,785			
Balance as at March 31, 2021	388,584			





	<b>Balance Sheet</b>		<b>Income Statement</b>		
	Consoli	idated	Conso	lidated	
	03/31/21	12/31/20	03/31/21	03/31/20	
Tax loss and negative basis	652,254	612,049	40,205	132,869	
Expected credit losses ("impairment") of trade receivables	43,085	42,672	413	3,503	
Expected disallowances variable consideration	23,093	20,081	3,012	1,167	
Provision Specialized medical services	(2,059)	(765)	(1,294)	(4,751)	
Miscellaneous provisions	104,940	76,262	28,678	4,852	
Provisions for obsolescence	2,777	2,687	90	(393)	
Adjustments to present value - APV	5,393	5,589	(195)	242	
Provision for contingencies	34,698	32,432	2,266	3,120	
Review of the useful life of property, plant and equipment	25,904	25,983	(79)	337	
Others	51,334	43,122	8,212	(382)	
Deferred in the reverse merger of subsidiary	303,227	301,202	2,025	(16,376)	
Amortization of goodwill	(660,797)	(656,175)	(4,621)	(4,378)	
Intangible assets identified in acquisitions that are not tax deductible	(59,675)	(60,551)	876	876	
Others	(3,968)	(4,300)	331	(100)	
Deferred income tax and social contribution	520,206	440,288	79,919	120,586	
Asset variation that does not affect the result					
Acquisitions of subsidiaries			-	(65,962)	
Deferred tax without tax loss used in the settlement of PERT			-	315	
Others			(24,340)	(260)	
			(24,340)	<u>(65,907)</u>	
			<u>55,578</u>	<u>54,679</u>	
Reflected in the balance sheet as follows:					
Deferred tax asset	522,051				
Deferred tax liability	(26,185)				
	495,866				
Deferred Tax Asset (Liability) Reconciliation					
Opening Balance - December 31, 2020	440,288				
Tax revenue recognized in income statement	55,578				
Others	(24,340)				
Balance as at March 31, 2021	495,866				

DASA Group Management considers the balances relating to active deferred income tax and social contributions resulting from temporary differences to be realized in the proportion of contingencies, and the realization of events originating the provisions for losses.

DASA Group did not identify indicators of non-recovery of deferred taxes in the period ended as at March 31, 2021.

Regarding active taxes resulting from fiscal losses and negative basis, Management estimates that tax credits will be recovered as demonstrated on the table below:

	Parent Company	Consolidated
2021	19,107	21,300
2022	59,742	66,600
2023	64,945	72,400
2024	68,982	76,900
after 2025	371,747	414,419
	<u>584,523</u>	<u>651,619</u>

(In thousands of reais, unless otherwise stated)



## 29 Information on business segments


For the purposes of assessing and decision-making by Management, as at December 31, 2019, the operations of the DASA Group were managed only by the outpatient care and care coordination services segments. With the acquisition of Ímpar Serviços Hospitalares S.A. in January 2020 and the growth in International Operations, DASA Group now operates with the following three strategic divisions, which correspond to its reporting segments: (i) services of outpatient care and care coordination. (ii) hospitals and oncology - with Ímpar Serviços Hospitalares S.A. and (iii) International Operations - assistance support services located in Argentina and Uruguay. The operating segment is reported consistently with management reports used by the main operational decision-maker (Chairman) when assessing segment performance and allocation of funds. The Chairman of the DASA Group assesses certain internal management reports from each division at least quarterly. The following summary describes the operations of each reportable segment:

Segments
Outpatient care and care coordination
Hospital and oncology
International Operations

Transactions
Diagnosis and health management
Medical and hospital services
Diagnostics

Geographic region Brazil Brazil South America (Argentina and Uruguay)

Segment performance was assessed based on net operating revenues, at the net profit (loss) and capital employed (total assets less current liability and non-current liability) for each segment.





The information for the periods ended as at March 31, 2021 and 2020 are shown below:

Outpatient care an	nd care coordination						
		Hospital ar	d oncology	y International Operations		T	otal
03/31/21	03/31/20	03/31/21	03/31/20	03/31/21	03/31/20	03/31/21	03/31/20
1,475,695 38,210	982,432	772,783	428,336	72,713 17,113	46,100	2,321,191 55,323	1,456,868
1,513,905	982,432	772,783	428,336	89,826	46,100	2,376,514	1,456,868
(473,348)	(274,132)	(126,198)	(85,349)	(6,330)	(17,325)	(605,876)	(376,806)
24,096	8,420	19,131	65,950	12,864	5,620	56,091	79,990
(127,327)	(137,595)	(51,366)	(81,142)	(1,358)	(1,059)	(180,051)	(219,796)
(151,467)	(126,499)	(56,332)	(29,913)	(3,252)	(8,137)	(211,051)	(164,549)
(18,150)	(103,055)	1,805	(24,968)	5,437	4,527	(10,098)	(123,496)
10,404,136	8,417,289	3,394,524	2,990,791	225,266	184,736	14,023,926	11,592,816
40,041 8,112,933	2,606 5,258,800	2,281,630	2,258,984	100,308	46,100	40,041 10,494,871	2,606 7,583,751
	03/31/21 1,475,695 38,210 1,513,905 (473,348) 24,096 (127,327) (151,467) (18,150) 10,404,136 40,041	03/31/21         03/31/20           1,475,695         982,432           38,210         -           1,513,905         982,432    (473,348)  (274,132)  24,096  (127,327)  (137,595)  (151,467)  (126,499)  (18,150)  (103,055)  10,404,136  40,041  2,606	03/31/21         03/31/20         03/31/21           1,475,695         982,432         772,783           38,210         -         -           1,513,905         982,432         772,783           (473,348)         (274,132)         (126,198)           24,096         8,420         19,131           (127,327)         (137,595)         (51,366)           (151,467)         (126,499)         (56,332)           (18,150)         (103,055)         1,805           10,404,136         8,417,289         3,394,524           40,041         2,606         -	03/31/21         03/31/20         Hospital and oncology 03/31/21         03/31/20           1,475,695         982,432         772,783         428,336	Hospital and oncology   Internation	Hospital and oncology   International Operations   03/31/21   03/31/20   03/31/21   03/31/20	Hospital and oncology   International Operations   O3/31/21   O3/31/21   O3/31/21   O3/31/21   O3/31/21   O3/31/20   O3/31/21   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/21   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/20   O3/31/21   O3/31/21   O3/31/20   O3/31/21   O3

(In thousands of reais, unless otherwise stated)



## 30 Financial instruments

### Accounting classification and fair values

The table below shows the book and fair values for assets and financial liabilities, including their fair value hierarchy. Information on the fair value of assets and financial liabilities not measured at fair value was not included if the book value is a reasonable approximation of fair value.

CONSOLIDATED ASSETS AND LIABILITIES		Book value			Book value Fair value		
March 31, 2021							
In thousands of reais	Note	Fair value through the result	Financial assets - Amortized cost	Financial liabilities - Amortized cost	Total	Level 2	Level 3
Financial assets measured at fair value							
Financial investments	5	684,109	-	-	684,109	684,109	_
Guaranteed with financial investment	19	38,666	-	-	38,666	38,666	_
Call option from non-controlling shareholders	19	5,423	-	_	5,423	-	5,423
Derivative financial instruments	30	71,599	-	-	71,599	71,599	_
Marketable securities	6	812,317	<u>-</u>		812,317	812,317	
		<u>1,612,114</u>			<u>1,612,114</u>	<u>1,606,691</u>	<u>5,423</u>
Financial assets not measured at fair value							
Cash and cash equivalents	5	-	66,930	-	66,930	-	-
Trade receivables	7	<del>-</del>	1,748,014		1,748,014		
			<u>1,814,944</u>		<u>1,814,944</u>		
Financial liabilities not measured at fair value							
Loans and borrowings	15	-	-	1,669,438	1,669,438	_	-
Debentures	17	-	-	4,158,515	4,158,515	-	_
Trade payables	14	-	-	864,866	864,866	-	-
Accounts payable from acquisition of subsidiaries	19	-	-	440,380	440,380	-	-
Lease payable	16		<u>=</u>	1,591,971	<u>1,591,971</u>	=	
			<del>_</del>	<u>8,725,170</u>	8,725,170		
Financial liabilities measured at fair value							
Put option granted to non-controlling shareholders	19	40,707	-	-	40,707		40,707
Contingent consideration (a)	19	72,273	<u>-</u>		72,273		72,273
		112,980	<u>=</u>		112,980		112,980

(In thousands of reais, unless otherwise stated)




CONSOLIDATED ASSETS AND LIABILITIES			Boo	k value		Fair value		
December 31, 2020								
In thousands of reais	Note	Fair value through the result and outros	Financial assets - Amortized cost	Financial liabilities - Amortized cost	Total	Level 2	Level 3	
Financial assets measured at fair value								
Financial investments	5	673,268	-	-	673,268	673,268	-	
Guaranteed with financial investment	19	38,505	-	-	38,505	38,505	-	
Call option from non-controlling shareholders	19	7,469	-	-	7,469	-	7,469	
Derivative financial instruments	30	65,404	-	-	65,404	65,404	-	
Marketable securities	6	<u>760,816</u>	Ξ	Ξ	<u>760,816</u>	760,816		
		<u>1,545,462</u>	≣	≞	<u>1,545,462</u>	1,537,993	<u>7,469</u>	
Financial assets not measured at fair value			-					
Cash and cash equivalents	5	-	80,339	-	80,339	-	-	
Trade receivables	7	<u>=</u>	1,745,886	=	1,745,886	=	Ξ	
		Ē	<u>1,826,225</u>	Ē	<u>1,826,225</u>	=	≞	
Financial liabilities not measured at fair value								
Loans and borrowings	15	-	-	1,201,815	1,201,815	-	-	
Debentures	17	-	-	4,137,008	4,137,008	-	-	
Trade payables	14	-	-	900,555	900,555	-	-	
Accounts payable from acquisition of subsidiaries	19	-	-	431,031	431,031	-	-	
Leases	16	Ξ	Ξ	1,485,513	1,485,513	Ξ.	=	
		Ē	≣	<u>8,155,922</u>	<u>8,155,922</u>	Ē	Ē	
Financial liabilities measured at fair value								
Put option granted to non-controlling shareholders	19	39,459	-	-	39,459	-	39,459	
Contingent consideration (a)	19	67,267	Ξ	Ξ	<u>67,267</u>	=	67,267	
		<u>106,726</u>	≣	≣	<u>106,726</u>	≞	<u>106,726</u>	

(a) This amount is linked to compliance with certain performance conditions related to Diagnósticos Maipú por Imágenes S.A. and Laboratório Nobel S.A. (i) Maípu: 2021 revenues from Diagnósticos Maipú por Imágenes S.A. which DASA Group believes will be achieved, based on results projections based on discounted cash flows, therefore, the fair value was recorded based on the maximum value, if it did not reach these conditions the value would be less than US\$ 10 million, equivalent to R\$ 56,973 (R\$ 51,967 as at December 31, 2020), resulting in US\$ 27,275 instead of US\$ 37,275. This amount will be paid in 2022. (ii) Laboratório Nobel: On the date of acquisition, the fair value of the contingent consideration was estimated at R\$ 15,300 (December 31, 2020 and March 31, 2021) based on the maximum amount. As at December 31, 2020, the main performance indicators for Laboratório Nobel S.A. evidenced the fulfillment of the stipulated goal.

The different levels were defined as follows:

- Level 1: Prices quoted (not adjusted) in active markets for identical assets and liabilities.
- Level 2: Inputs, except for quoted prices, included in Level 1 which are observable for assets or liabilities, directly (prices) or indirectly (derived from prices).
- Level 3: Assumptions, for assets or liabilities, which are not based on observable market data (non-observable inputs).





Generally, the DASA Group is exposed to the following risks arising from their operations and that may affect, to a greater or lesser degree, our strategic and financial objectives:

- market risk
- liquidity risk
- · credit risk
- operating risk

The DASA Group manages risks to which we are exposed by defining conservative strategies, to achieve liquidity, profitability and security, in accordance with objective criteria for risk diversification.

There were no transfers between levels of measurement within the fair value hierarchy in the period ended as at March 31, 2021 for those assets and liabilities.

### Measurement of fair value

Valuation techniques and significant, non-observable data:

The tables below show the valuation techniques used in measuring the fair values at levels 2 and 3 for financial instruments measured at fair value in the balance sheet, as well as the significant non-observable data used. The valuation processes are:

Туре	Valuation techniques	Significant unobservable inputs	Relationship between significant unobservable data and measurement of fair value	
Financial investments and Marketable securities	Bank deposits remunerated in CDBs remunerated by the fluctuation of the CDI rate, with effective compensation ranging from 89.76% to 102.86%. They are not sold and are settled directly with a counterparty, so that the book value reported consists of a reasonable approximation of the fair value	Not applicable	Not applicable	
Put option granted to non- controlling shareholders and expected gain in relation to the acquisition (included in "accounts payable for the acquisition of subsidiaries")	Discounted cash flows: the valuation model considers the present value of expected future payments, discounted at a riskadjusted rate of discount.	Discount adjusted to risk (March 31, 2021: 5.34% p.a.)	Estimated fair values would increase (decrease) if the risk-adjusted rate of discount was lower (higher)	
Derivative financial instrument (foreign exchange swap)	The most frequently applied techniques include a pricing model with present-value calculations on forward exchange rates quoted in the market.	Not applicable	Not applicable	

### Financial instrument not measured at fair value

Туре	Valuation techniques	Significant unobservable inputs
	Discounted cash flows: The valuation model considers	
Amortized cost	the present value of the expected payment, discounted	Discount rate
	by a risk-adjusted rate of discount.	

The fair values for the cash and bank balances, accounts receivable from customers, suppliers and accounts payable are equivalent to their book values, mainly due to the short-term maturity of these instruments.

(In thousands of reais, unless otherwise stated)



### Risk management structure

Aligned with the regulations in force and corporate policies of the DASA Group, the system is based on the integrated management of each of the business processes and in the adequacy of the level of risk to the established strategic objectives. The risk management process enjoys a corporate governance structure that engages from Higher Management and institutional committees, responsible for among other attributions, supervising the effectiveness and integrity of internal control processes and risk management, to the various areas within the DASA Group, in the identification, treatment and monitoring of those risks.

The internal controls environment at the DASA Group was designed to support the nature, risk and complexity of our operations, based on formalized policies and procedures disclosed to the entire organization, as well as dedicated areas and specific tools for risk monitoring.

Integrated management of all risks inherent to our activities is approached according to a process that is supported by Internal controls and Compliance structures (regarding regulations, standards and internal policies) that provides for the continuous improvement of risk management models and minimizes any gaps that may compromise the correct identification and measurement of risks. After the identification, valuation and monitoring of the main risks, specific plans of action are identified, ensuring improvements are implemented.

Historically, the financial instruments contracted by the DASA Group have shown adequate results in mitigating risks. In addition, the DASA Group does not perform transactions involving exotic or speculative derivatives.

#### Market risks


These are risks related to assets and liabilities which cash flows or present values are exposed to the following:

### Foreign exchange risk

- (a) DASA Group has accounts payable from the acquisition of subsidiaries in US dollar, and we considered the scenarios below for purposes of determination of the volatility between the Brazilian real and the US dollar.
  - Scenario 1: (25% of appreciation of the Brazilian real) parity R\$/US\$ of 4.27
  - Scenario 2: (50% of appreciation of the Brazilian real) parity R\$/US\$ of 2.85
  - Scenario 3: (25% of depreciation of the Brazilian real) parity R\$/US\$ of 7.11
  - Scenario 4: (50% of depreciation of the Brazilian real) parity R\$/US\$ of 8.54

		_	Income (Expense) with exchange rate variation in R\$				
	Balance R\$	Reference amount US\$	Scenario 1	Scenario 2	Scenario 3	Scenario 4	
Dollar Rate		5.6973	4.27	2.85	7.11	8.54	
Accounts payable for acquisition of subsidiary Loans in USD	269,142 377,580	47,301 66,359	201,975 283,351	134,808 189,122	336,309 471,809	403,950 566,702	
Financial income - income (expense)			161,396	322,793	(161,396)	(323,929)	

(b) With the acquisition of our subsidiary Ímpar, as shown in Note 2, DASA Group assumed loans contracted in foreign currency (US dollars) that have derivative financial instruments contracted to protect against exchange rate fluctuations in the acquisition of services in foreign currency.





Derivative instruments as at March 31, 2021:

Swap			
	Current	Non-current	Total
Assets	18,590	53,009	71,599
Liabilities	(2,717)	(7,584)	(10,301)
	15,873	45,425	61,298
Derivative instruments as at December 31, 2020:			
Swap			
	Current	Non-current	Total
Assets	25,189	37,516	62,705
Liabilities	(812)	(5,603)	(6,415)
	24.377	31.913	56,290


As at March 31, 2021, consolidated quarter information had derivative agreements to hedge against exchange rate fluctuations for all outstanding foreign currency loan agreements. The summaries of the open agreements are shown below:

			Perc	entage	Val	idity	
Swap Rates Exchange Agreement (pre-CDI)	Par value US\$	Balance of loans in foreign currency as at 03/31/21	Original index	Swap	Beginning	Maturity	Unrealized gains / (losses) on derivatives instruments as at 03/31/21
Santander	27,413	156,182	4.45%	CDI + 1.35% p.a.	11/12/2019	10/04//2024	41,149
Itaú BBA	8,823	50,268	4.45%	CDI + 0.95% p.a.	07/05/2018	07/06/2021	15,990
							57,139

#### **Interest rate risk**

a) The interest rate variation risk may increase or decrease our finance income. The fixed interest rate held to maturity guarantees the cash flows. The floating interest rate implies volatility to the future interest disbursement. The main tool for controlling the risk related to the interest rate will be the treasury Department's daily position, which will be based on reports provided by BM&F Bovespa to control the interest rates involved in our operations.

The main market risks to the DASA Group comprise the possible changes in interest and foreign exchange rates. As a result, DASA Group seeks protection against liquidity risks with financial instruments such as financial investments, working capital loans, fund raising through the issuance of debentures, all of those under normal market conditions.





All financial operation is submitted to the DASA Group Executive Committee and subsequently for validation by the Board of Directors and/or its auxiliary advisory bodies. In the case of currency exposure and interest exposure, the guidelines are defined by the Board of Directors and operationalized by the Treasury, as they depend on variables that make up the economic scenario. The Treasury provides the Executive Committee with an updated position on the DASA Group's exposure to market risks on a monthly basis, by submitting reports, documents and agreements, which allows verification of compliance with the Policy.

In addition, for market risks to which the DASA Group is exposed, the Treasury is required to perform a monthly analysis of the sensitivity test (*stress test*), at fluctuation rates of 25% and 50% in relation to the original rates, in order to assess the elasticity of these positions when subjected to large fluctuations in the rates involved in these transactions and their impact on DASA Group's results and cash positions.

### Liquidity risk

Liquidity risk is the risk that an unexpected event may take place or any incorrect calculation in terms of necessary liquidity, which may impact the DASA Group investment or daily decisions.

DASA Group manages its liquidity risk maintaining reserves, bank credit lines and credit lines for the funding of loans it deems appropriate, performing continuous monitoring of actual and expected cash flows and matching the maturity profiles of financial assets and liabilities, following the targeting above:

- a) Management of short-term cash Management of net assets and credit lines to cover immediate needs. Frequency: Daily. Term: D+1 (in business days);
- b) Management of long-term cash Continuous procedure to ensure long-term funds, based on the analysis of the cash budget on a monthly basis, update of the assumptions in accordance with the business needs and comparison between used and estimated cash. Frequency: Monthly. Term: 5<sup>th</sup> business day of the month after the base date of the report;
- c) Maintenance of minimum cash Refers to the cash balance that the DASA Group recovers in a very short period to meet the urgent needs. In addition, the criteria adopted considers that the DASA Group must have sufficient funds to cover the five worst daily flows in the month, not including receipts; and
- d) Exposure limits and risk reduction The treasury area has, for short term, immediately liquid cash investments and working capital lines, which is sufficient to ensure at least the amount equal to the five consecutive days of highest cash outflows over the last 12 months.

For medium and long terms, the treasury area has credit lines compatible with the strategic planning adopted by the DASA Group, always in order to ensure the available funds to meet the expected cash flow.

The table below shows the details of the maturity of the consolidated financial liabilities contracted as at March 31, 2021:

Operation	2022	2023 to 2024	after 2025	Total
Derivative financial instruments	25,894	19,531	_	45,425
Trade payables	15,357	-	-	15,357
Bank loans and borrowings	828,768	170,523	14,804	1,014,095
Debentures	924,719	919,734	1,847,063	3,692,056
Taxes in installments	9,833	34,070	12,871	56,774
Payable from acquisition of subsidiaries	262,790	93,047	22,462	378,299
	2.067,361	1,236,905	<u>1,897,740</u>	5,202,006

(In thousands of reais, unless otherwise stated)



As at March 31, 2021, the Parent Company's current liabilities overstated current assets by R\$ 408,613 (as at December 31, 2020, such amount was not above). Management understands that the proceeds from the restricted offering of shares (Note 33) will balance the current capital. Therefore, this individual and consolidated interim financial information has been prepared based on the assumption that the DASA Group will continue as a going concern.

### **Credit risk**

Refers to the risk of loss resulting from the counterparty's incapacity to comply with the obligations to pay DASA Group, as set forth in the agreement. This risk will be mainly reduced by credit analysis, and the measurement of this risk, in the future, will be mainly based on the determination of expected losses for allowance for loan losses and expected losses for variable consideration (disallowance).

The DASA Group is subject to the credit policy defined by its Management and aims at reducing possible issues arising from the violation relating to the disallowances of the plans. In addition, the DASA Group has recognized an allowance for loan losses, disallowances and checks returned in the parent company, accounting for 7.62% as at March 31, 2021 (7.57% as at December 31, 2020) of the outstanding accounts receivable and, in the consolidated, accounting for 7.76% (7.98% as at December 31, 2020) of the outstanding accounts receivable against credit risk.

As at March 31, 2021, the maximum exposure, in the consolidated, totaled R\$ 2,459,188 (R\$ 2,459,644 as at December 31, 2020) relating to the cash and cash equivalents and accounts receivable from customers.

### **Operating risk**

Operating risk is the risk of direct and indirect losses derived from a series of reasons associated to processes, personnel, technology and infrastructure of the DASA Group and of external factors, except for credit, market and liquidity risks, such as those resulting from legal and regulatory requirements and generally accepted standards of corporate behavior. Operating risks arise from all the operations of the DASA Group.

The purpose of the DASA Group is to manage the operating risk so as to avoid the occurrence of financial losses and damages to the reputation of the DASA Group and to seek efficacy of costs and to prevent control procedures restricting initiative and creativity.


The Senior Management is mainly responsible for the development and implementation of operational risk controls. The Senior Management is supported by the development of general standards of the DASA Group for purposes of operational risk management.

### The amounts are disclosed net of transaction costs

The DASA Group may change its capital structure, according to the economic, financial, strategic and operational conditions, in order to improve the debt management. At the same time, the DASA Group seeks to improve the return on invested capital (ROIC) through the implementation of a working capital management and an efficient investment program.

### Sensibility analysis of the financial assets and liabilities

The main risks associated with the operations of DASA Group are associated with the CDI variation for Promissory Notes, Debentures and financial investments, subject to the US dollar variation for bank loans and financing and financial investments.





The investments by the CDI are registered at market value, according to the price disclosed by the respective financial institutions, and the others mostly refer to bank deposit certificates and repurchase operations, therefore, the registered value of these securities does not differ significant from the market value.

In order to verify the index sensibility in the consolidated financial statements, applicable to the DASA Group as at March 31, 2021, the scenarios were defined according to the projections, based on which the 25% and 50% variations were calculated.

Financial expense / (financial revenue) was calculated for each scenario not taking into account the levy of taxes and maturity flow of each agreement scheduled for 2021. Considering that the financial result is not generated, the investments that guarantee the payments of contingencies payable to the acquirees, in the amount of R\$ 38,667, as at March 31, 2021, were not considered in this projection.

Operation	<b>Balance as at 03/31/21</b>	Risk(a)	Scenario I (Probable)	Scenario II	Scenario III
Financial investment	1,496,369	CDI	89,782	67,337	44,891
			6.00%	4.50%	3.00%

In order to determine the sensibility of the index in the debts, in the Consolidated, applicable to DASA Group as at March 31, 2021, three scenarios were identified according to the projection, based on which the 25% and 50% variations were calculated.

Financial expense was calculated for each scenario not taking into account the levy of taxes and maturity flow of each agreement scheduled for 2021. The base date used to the financing was March 31, 2021, forecasting the indexes for one year and verifying the sensitivity in each scenario.


			Scenario I		
Operation	Balance as at 03/31/21	Risk(a)	(Probable)	Scenario II	Scenario III
Debentures	4,167,828		250,070	312,587	375,105
Promissory Notes	1,156,025		69,362	86,702	104,042
			6.00%	7.50%	9.00%

## 31 Related parties

In the periods ended March 31, 2021 and 2020, the Company carried out related-party transactions, broken down as follows:

### Operations related to the provision of services between the Company and its subsidiaries

_	Current asset customers		Current liability - Other trade payables		Revenue from services		Cost of services rendered	
	03/31/21	12/31/20	03/31/21	12/31/20	03/31/21	03/31/20	03/31/21	03/31/20
CientificaLab	2,579	5,635	_	_	3,293	965	-	_
Previlab	1,123	1,463	-	-	3,296	1,481	-	-
Gaspar	712	569	-	-	1,823	439	-	-
Salomão Zoppi	11,944	22,926	-	-	5,002	-	-	-
Santa Luzia	1,966	2,325	-	-	2,827	518	-	-
Deliberato	, -	, -	-	-	762	760	-	-
Padrão Ribeirão	304	304	-	-	_	32	-	-
Valeclin	-	1	-	-	1	198	-	-
Insitus	12	17	-	-	38	68	-	-
Ruggeri	_	247	_	_	338	343	-	_
São Camilo	112	-	-	-	-	-	-	-
Itulab	406	406	1,356	-	380	104	-	-
Dresch	10	10	, -	_	_	_	_	_





	Current custom		Current liability - Other trade payables				Cost of services rendered	
	03/31/21	12/31/20	03/31/21	12/31/20	03/31/21	03/31/20	03/31/21	03/31/20
CPCLIN	30	9	-	-	35	15	_	-
CRMI Petrópolis	-	-	-	-	-	-	-	145
DASA RE (i)	-	-	74	69	-	-	204	261
Ímpar	14,949	16,687	-	-	18,872	11,190	-	-
HSP	-	3,384	-	-	61	3,844	-	-
Genia - MOL	130	130	-	-	-	-	-	-
Bioclinico	380	351	-	-	487	-	-	-
Allbrokers	-	-	38	-	-	-	-	-
São Marcos	494	-	-	-	494	-	-	-
Hemat	-	-	-	-	21	-	-	-
Exame					<u>252</u>	<del></del>		
	<u>35,151</u>	54,464	<u>1,468</u>	69	37,982	<u>19,957</u>	_ 204	406

<sup>(</sup>i) Revenues from leased real estates.

The related-party transactions, as referred to above, are carried out at cost and eliminated in the consolidated quarterly information.

Related parties - Loan agreements entered into between the Company and its subsidiaries as at March 31, 2021 and December 31, 2020

	Compensatory			
	rate	Maturity	12/31/21	12/31/20
Loan agreement				
Padrão Ribeirão	120% of CDI	08/20/2022	2,053	1,543
DB Genética	120% of CDI	12/31/2023	14,117	12,043
			<u>16,170</u>	<u>13,586</u>

The result from loan agreements entered into between the Company and its subsidiaries totaled R\$ 224 for the period ended March 31, 2021.

Related parties - Dividends and interest on own capital receivable by the Company from its subsidiaries as at March 31, 2021 and December 31, 2020 are broken down as follows (Note 10):

	03/31/21	12/31/20
CientificaLab	2,416	2,416
Salomão Zoppi	4,662	4,662
Impar Services Hospital	30,990	30,990
CRMI Petrópolis	3,328	1,739
DB Genera	265	265
Valeclin	4,150	1,387
Deliberato	1,004	1,004
Gaspar	3,108	3,108
Previlab	3,373	3,373
DASA RE	1,533	1,533
Cromatox	1,565	1,565
	<u>56,394</u>	52,042

### Other receivables

Specialized medical services shared between the Company and its subsidiary Salomão and Zoppi, recognized in line item "Other credits", in the amount of R\$ 13,906 (R\$ 5,603 as at December 31, 2020).

(In thousands of reais, unless otherwise stated)



### **Management's compensation**

The Management's compensation totaled R\$ 16,294 in the first quarter of 2021 (R\$ 9,813 in the first quarter of 2020), including fixed compensation and bonus, out of which R\$ 1,491 in the first quarter of 2021 (R\$ 942 in the first quarter of 2020) paid to the members of the Board of Directors (composed of six members in the first quarter of 2021 and three members in the first quarter of 2020), and R\$ 14,803 in the first quarter of 2021 (R\$ 8,871 in the first quarter of 2020) paid to the statutory executive officers (composed of 18 statutory executive officers in the first quarter of 2021 and 11 executive officers in the first quarter of 2020). The changes in the share-based compensation are disclosed in Note 21 (a). There are no additional benefits directed to the Company's management.

According to Note 21, Management is entitled to the share-based payment and the carrying amount of the program is R\$ 112,617 as at March 31, 2021 (R\$ 31,820 as at December 31, 2020). The disbursement/payment of cash, as at March 31, 2021, totaled R\$ 1,168 (R\$ 69,130 as at December 31, 2020). There was no disbursement/payment of cash in 2019 to the Company's management in relation to such plan.

There are no additional benefits to the Company's management.

### Operations carried out between the Company and other related parties

The operations between related parties are carried out based on the amounts, terms and rates agreed between the parties, in effect on the respective dates, on a continuous basis.


The related parties included in the individual quarterly Information are:

- Link Consultoria em Medicina Diagnóstica Ltda.: company controlled by Alcione Moya Aprilante, quotaholder of Previlab Análises Clínicas Ltda., which is controlled by the Company and provides regional consulting services specialized in the management of companies that operate in the medical area, with knowledge of the market, relationship with the doctors of the region where Previlab operates and renowned professionals of the health and customer area.
- Amar Administradora de Bens Próprios Ltda.: company onwed by Alcione Moya Aprilante and his wife, Melania Angelieri Cunha Aprilante. Mr. Alcione is the quotaholder of Previlab (company controlled by the Company), which leased the real estates owned by AMAR, owned by Melania Angelieri Cunha Aprilante.
- **César Antonio Biazio Sanches**: quotaholder of Previlab Análises Clínicas Ltda., owner of the real estate leased to Previlab, which is controlled by the Company.
- A e C Consultores Ltda.: company controlled by Cezar Antonio Biazio Sanches, quotaholder of Previlab Clinical analyses Ltda., which is controlled by the Company and provides business consulting and advisory services in the sector where Previlab operates, in addition to consulting services, training and valuation of professionals of the Previlab's employees and service providers.
- **Pesmed Pesquisas e Serviços Médicos Ltda.**: Pesmed's partner is Mr. Emerson Leandro Gasparetto, the Company's executive doctor (elected on March 26, 2012), in addition to his wife, also a doctor, Taisa Pallu Davaus Gasparetto, both compensated for the provision of consulting services in medical studies and researches to the Company. The amounts are calculated based on the revenues from imaging services and number of medical exams produced by Pesmed, according to the value equivalent to each type of medical exam, according to the Company's table and the same system adopted for the Company's other service providers.

(In thousands of reais, unless otherwise stated)



- RMR Ressonância Magnética Ltda.: the partners jointly hold 80% of the capital stock and are brothers of Mr. Romeu Cortês Domingues, the Company's Board of Directors' CEO (elected on April 26, 2011), which provides magnetic resonance imaging services to the Company. The amounts are calculated based on the revenues from imaging services and number of medical exams produced by RMR, according to the value equivalent to each type of medical exam, according to the Company's table and the same system adopted for the Company's other service providers.
- Ultrascan Services de imagem Ltda.: the Ultrascan's partner is Mr. Eduardo Luiz Primo de Siqueira, who holds an equity interest of 7.5% in Clínica de Ressonância Multi-Imagem Petrópolis Ltda., which provides technical imaging services to subsidiary Clinica de Ressonância Multi-Imagem Petrópolis Ltda. The amounts are calculated based on the revenues from imaging services and number of medical exams produced by Ultrascan, according to the value equivalent for each type of medical exam, according to the subsidiary's table and the same system adopted for the subsidiary's other service providers.
- ECRD Services Médicos de Radiologia Ltda.: the ECRD's partner is Mr. Roberto Cortes Domingues, the brother of Mr. Romeu Cortês Domingues, the Company's Board of Directors' CEO, which provides medical services in magnetic resonance imaging and radiology to the Company.
- PTR 7 Investimentos Imobiliários Ltda.: company that leased real estates to the Company and its subsidiaries. Mr. Pedro de Godoy Bueno is the PTR's direct shareholders, and the Company's shareholder and CEO. The indirect shareholders are Camilla de Godoy Bueno Grossi and Dulce Pugliese de Godoy Bueno, the Company's shareholders.
- Ecolimp Systems de Services Ltda.: company that provides cleaning and maintenance services to the Company, controlled by Mr. Rodolpho Ricci, cousin of the CEO, Mr. Pedro de Godoy Bueno.
- Conexa Health Services Médicos Ltda.: company that provides services to the Company and is controlled by Fernando Domingues, the son of Mr. Romeu Cortês Domingues, the Company's Board of Directors' CEO.
- BFL Empreendimentos Imobiliários Ltda.: company controlled by Mr. Romeu Cortês Domingues, the Company's Board of Directors' Chairman, which entered into the real estate lease agreement with the Company.
- Seven Seas Partner Saúde e Prevenção Ltda.-ME: the Company's franchisee, controlled by Mr. Romeu Cortês Domingues, the Company's Board of Directors' Chairman, which entered into the service agreement.
- VIDA Posto de Coleta Ltda.: the Company's franchisee, controlled by Natasha Slhessarenko Fraife Barreto, the Company's medical executive officer, which entered into the franchise agreement.
- Localiza Rent a Car S.A.: company that provides car rental services to the Company. Mr. Pedro de Godoy Bueno is the Localiza's shareholder and the Company's shareholder and CEO.
- **EDAN Services De Coleta Ltda.**: the Company's franchisee, controlled by Mr. Danilo Rodrigues, spouse of Claudia Cohn, the Company's executive officer, which entered into the franchise agreement.
- Essijota Serviços de Coleta e Diagnósticos Ltda.: the Company's franchisee, controlled by Mr. Sérgio Jr, cousin of the CEO, Mr. Pedro de Godoy Bueno, which entered into the franchise agreement.
- Signo Propriedades Investimentos Imobiliários Ltda.: company that leased real estates to the Company and its subsidiaries. Mr. Pedro de Godoy Bueno is the Signo's direct shareholder; Company's shareholder and CEO. Signo's indirect shareholders are Camilla de Godoy Bueno Grossi and Dulce Pugliese de Godoy Bueno, who are the Company's shareholders.
- Fundo de Investimento em Participações Genoma III Multiestratégia: majority shareholder of the Company's subsidiary through January 2020.





- Socec Serviços Médicos SS Ltda.: company that leased real estates to the Company and its subsidiaries. Mr. George Schahin is a shareholder and director of Socec Serviços Médicos SS Ltda., which is controlled by the Company.
- **José de Oliveira Domingos**: Estate of Mr. José, represented by Mr. Romeu Cortês Domingues, the Company's Board of Directors' Chairman, leased a real estate to the Company.
- CM Hospitalar S.A.: company that provides hospital services to the Company and its subsidiaries. Mr. Pedro de Godoy Bueno is the CM Hospital S.A.'s shareholder, and also the Company's shareholder and CEO.

The intercompany operations are broken down as follows:

	Balances Assets / (Liabilities) as at 03/31/21			Balances Assets / (Liabilities) as at 12/31/20		
	Services	Rentals	Others	Services	Rentals	Others
- Link Consult. em Medicina Diag. Ltda.	(16)	-	-	(16)	-	_
<ul> <li>Amar Admin. de Bens Próprios Ltda.</li> </ul>	-	(33)	-	-	(33)	-
- César Antonio Biazio Sanches	-	(6)	-	-	(8)	-
- A and C Consultores Ltda.	(23)	-	-	(23)	-	-
<ul> <li>PTR7 Investimentos Imobiliários Ltda.</li> </ul>	-	(1,688)	-		(1,374)	-
<ul> <li>Ecolimp Systems de Services Ltda.</li> </ul>	(5,562)	-	-	(4,638)	-	-
- Fundo Invest. em Particip. Genoma - Dividends	-	-	(80,925)	-	-	(46,761)
<ul> <li>Patrys Investimentos Imobiliários Ltda.</li> </ul>	-	(7,160)	-	-	-	-
<ul> <li>Socec Empreendimentos Imobiliários Ltda.</li> </ul>	-	(285)	-	-	-	-
- Multi-strategy - Dividends	-	-	(5,923)	-	-	-
- Shareholder -Individual - Dividends	-	-	(309)	-	-	-
- BFL Empreendimentos Imobiliários Ltda.	-	(183)	-	-	(175)	-
- Seven Seas Partner Health and Prev. Ltda.	(100)	-	-	(121)	-	-
- VIDA - Posto de Coleta Ltda.	-	-	-	(83)	-	-
- Conexa Health Services Médicos Ltda.	(113)	-	-	(100)	-	_
<ul> <li>JNZ Participações S/A</li> </ul>	` <u>-</u>	-	-	` -	(114)	-
- Localiza Rent a Car S.A.	(3)	-	-	(3)	-	_
- José de Oliveira Domingues	-	(202)	-	-	(15)	-
- CM Hospitalar	(13)	-	-	(7,860)		-

	Income / (Expenses) 03/31/21			Income / (Expenses) 03/31/20		
	Services	Rentals	Others	Services	Rentals	Others
- Link Consult. em Medicina Diag. Ltda.	(48)	-	_	(48)	-	-
<ul> <li>Amar Admin. de Bens Próprios Ltda.</li> </ul>	-	(100)	-	-	(94)	-
- César Antonio Biazio Sanches	-	(24)	-	-	(26)	-
- A e C Consultores Ltda.	(66)	-	-	(67)	-	-
- Pesmed - Pesq. and Serv. Médicos Ltda.	(151)	-	-	(279)	-	-
- RMR Ressonância Magnética Ltda.	(649)	-	-	(679)	-	-
- Ultrascan Services de imagem Ltda.	(33)	-	-	(56)	-	-
- ECRD Serv. Médicos de Radiologia Ltda.	(714)	-	-	(802)	-	-
<ul> <li>PTR7 Investimentos Imobiliários Ltda.</li> </ul>	-	(5,425)	-	-	(4,282)	-
- Patrys Investimentos Imobiliários Ltda.	-	(23,218)	-	-	(70,043)	-
- Ecolimp Systems de Services Ltda.	(11,591)	-	-	(50,307)	-	-
- Esho Empresa de Services	-	-	-	(3)	-	-
<ul> <li>Socec Empreendimentos Imobiliários Ltda.</li> </ul>	-	(839)	-	-	-	-
- Signo Properties Invest. Imobiliários Ltda.	(103)	-	-	(366)	-	-
- BFL Empreendimentos Imobiliários Ltda.	-	(533)	-	-	(511)	-
- Seven Seas Partner Health and Prev. Ltda.	(390)	-	-	(196)	-	-
- VIDA - Posto de Coleta Ltda.	(485)	-	-	(139)	-	-
<ul> <li>Conexa Health Services Médicos Ltda.</li> </ul>	(322)	-	-	(12)	-	-
<ul> <li>JNZ Participações S/A</li> </ul>	-	-	-	-	(341)	-
- Localiza Rent a Car S.A.	(22)	-	-	(106)	-	-
- EDAN Services de Coleta Ltda.	(678)	-	-	(246)	-	-
<ul> <li>Essijota Serv. de Coleta and Diag. Ltda.</li> </ul>	(144)	-	-	(102)	-	-
- José de Oliveira Domingues	-	(597)	-	-	-	_
- CM Hospitalar	(30)		-	(30)	-	-

### 32 Insurance coverage

As at March 31, 2021, the insurance coverage totaled R\$ 6,645,362, out of which R\$ 1,659,342 refers to loss of profits, R\$ 4,981,019 to material damages and R\$ 5,000 to professional civil responsibility.

(In thousands of reais, unless otherwise stated)



### 33 Subsequent events

### Nossa Senhora do Carmo Participações S.A.

A meeting of the board of directors held on September 15, 2020, approved the acquisition by Ímpar Serviços Hospitalares, a wholly-owned subsidiary of our Company, of a 70% ownership interest on Nossa Senhora do Carmo Participações Ltda., that provides medical, outpatient, hospital, clinical and surgical services, including medium and high complexity procedures, diagnostic imaging services and laboratories in the State of Rio de Janeiro.

After the performance of the suspensive conditions and applicable approvals, the operation will be submitted to the shareholders' ratification by virtue of the next Shareholders' Meeting to the held, under the terms of paragraph 1, article 256, of Law 6404/76.

The acquisition was concluded on April 1, 2021, after CADE's approval and performance of the suspensive conditions and applicable approvals, at the value of R\$ 115,728, divided into: i) R\$ 40,943 in cash, on April 3, 2021, ii) R\$ 25,243 payable on April 1, 2022, iii) R\$ 25.543 payable on April 1, 2023, and iv) R\$ 25,000 payable on April 1, 2024.

Through the disclosure of the disclosure date of the individual and consolidated interim financial information, the Management had not concluded yet the study on the fair values of the assets acquired and liabilities assumed for purposes of definition of the allocation of the price paid.

### Acquisition of controlled companies - Hospital Leforte Liberdade S.A.

At the Board of Directors meeting held on December 15, 2020, the acquisition of 100% of the capital of Hospital Leforte Liberdade S.A. was approved for approximately R\$ 1,770,000,000. The downpayment was performed in the amount of R\$ 200,000 (Note 10). The purpose of the Hospital Leforte Liberdade S.A. is to provide medical, outpatient, hospital, clinical and surgical services in the State of São Paulo, including medium and high complexity procedures, diagnostic imaging and laboratory services.


After the fulfillment of suspensive conditions and applicable approvals, the transaction will be submitted for ratification by shareholders at the next Shareholders' Meeting, pursuant to article 256-1 of Law No. 6,404/76. Until the end of the first quarter of 2021, compliance with suspensive conditions and applicable approvals has not been completed.

In December 2020 and February 2021, the Company paid the vendors (Hospital Leforte Liberdade S.A.) the amounts of R\$ 200,000,000 and R\$ 100,427,000 respectively, as down-payment under the acquisition agreement. The amount paid in December 2020 was recorded in current assets, as an advance payment for the acquisition of subsidiaries (Note 10).

### Acquisition of subsidiary - Hospital São Domingos Ltda.

At the Board of Directors' meeting held on March 12, 2021, the acquisition of 100% of the capital of Hospital São Domingos Ltda. was approved for R\$ 400,000. Hospital São Domingos Ltda. provides, in the State of Maranhão, medical, outpatient, hospital, clinical and cirurgical services, offering complete health care.

The completion of the operation is subject to the performance of some conditions precedent, including: (i) the approval of the terms and conditions of the Operation by the Administrative Council of Economic Defense (CADE), as set forth in Law 12529, of November 30, 2011; and (ii) the approval of the shareholders' meeting for implementation of the operations set forth in the agreement, in conformity with the terms set forth in paragraph 1, article 256, of Law 6404/76.





### Incorporation of subsidiary - Insitus Serviços Médicos e Laboratórios Ltda.

On April 14, 2021, Management approved the incorporation of jointly-controlled subsidiary Insitus Serviços Médicos e Laboratórios Ltda. The incorporation is aligned with the strategy for optimization of the corporate and business structures of DASA Group. Accordingly, the purpose is the reduction of costs in administrative areas and the performance of supplementary obligations, in addition to the more efficient joint management in the use of synergies, which will result in equity and financial benefits on behalf of DASA Group and the merged company.

Such transaction was carried out on May 1, 2021 and did not impact the individual and consolidated interim financial information as at March 31, 2021.

### Incorporated assets and liabilities

	R\$ thousand
Assets	
Cash and cash equivalents	1,026
Trade receivable	637
Other receivables	147
Property, plant and equipment and intangible asset	823
Total assets	2,633
Liabilities	
Trade payables	(840)
Labor and social obligations	(110)
Other accounts payable	(432)
Total liabilities	(1,382)
Incorporated net assets	1,251


### **Restricted Offering of shares**

The Board of Directors' meeting, held on April 6, 2021, approved the public offering for primary distribution of the registered, book-entry common shares, with no par value, free and clear of any burden or encumbrances ("Shares"), issued by the Company, with restricted placement efforts, under the terms of CVM Instruction 476 ("Restricted Offering").

The price per share was defined at R\$ 58.00 ("Price per Share"), totaling R\$ 3,306,626, and the effective increase in the Company's capital stock totaled R\$ 3,306,626, upon the issuance of 57,010,786 new shares, including the respective approval.

Due to the increase of the capital stock, within the scope of the Restricted Offering, the new capital stock of the Company is R\$ 15,633,332 represented by 537,824,544 common shares all registered book entry and with no par value. Out of the proceeds received by the Company arising from the Restricted Offering, the total proceeds were allocated to the capital stock; therefore, no proceeds were allocated to the capital reserve.

The shares under the Restricted Offering were began to be traded in B3 S.A. - Brasil, Bolsa, Balcão ("B3") on April 8, 2021, considering that the physical and financial settlement of the shares took place on April 9, 2021 ("Settlement Date").





The total net proceeds from the Primary Offering will be allocated to the (i) organic and inorganic growth (strategic acquisitions); (ii) payment relating to the acquisition of Leforte Group (Biodínamo Empreendimentos and Participações Ltda.), according to the material fact disclosed on December 3, 2020; (iii) working capital for the Company's businesses, including the investment in new products and researches.

### Restricted offering of shares

At the Board of Directors' meeting held on May 10, 2021, the Company's capital increase was approved, within the limit of its authorized capital, in the amount of R \$ 359,647,386.00, which will increase from R\$ 15,633,588.39 to R\$ 15,992,978.97 through the issuance of 6,200,817 new common shares, each in the amount of R\$ 58.00, all registered, book-entry and without par value, passing the Company's capital stock, until then divided into 541,762,371 common shares, to be divided into 547,963,188 common shares, all registered, book-entry and without par value, excluding the preemptive right of the current shareholders of the Company in the subscription, in accordance with the provisions of article 172, item I, of the Brazilian Corporation Law, and pursuant to article 6 of the Company's Bylaws, due to the partial exercise of the Supplementary Shares option by Banco BTG SA, within the scope of the Offer. They also approved that the new shares issued will have the same rights conferred to the other shares of the Company, under the terms of the Company's Bylaws and applicable legislation, being entitled to the full receipt of dividends and other earnings of any nature that may be declared. for the Company.

**Pedro de Godoy Bueno** Chief Executive Officer Felipe da Silva Guimarães Chief Finance and Administrative Officer

Tiago Garcia Moraes Administrative and Financial Superintendent CRC 1SP280542/O